🏷

Classifications

Harrison's Part

◆

Subtypes

2

Placenta previa (placenta covering the internal cervical os)

The placental edge overlies the internal os. This is the form that persists into the third trimester far more often than a merely low-lying placenta does, and it is the form that mandates abdominal delivery.

Show evidence (1 reference)

PMID:31671480 SUPPORT Human Clinical

"Low-positioned placenta included placenta previa, defined as a placenta covering the internal os of the cervix, and a low-lying placenta, defined as a placenta lying near to (within 20 mm) but not overlying the internal os."

States the covering-versus-near definition that separates the two contemporary subtypes.

Low-lying placenta (edge within 20 mm of the internal os, not covering)

The placental edge lies within 20 mm of the internal os without overlying it. It is worth separating rather than treating as a milder grade of the same thing: in the second trimester it persists to the third in about 1 in 70 cases against 1 in 5 for a covering placenta, and above a 2 cm placenta-to-os distance vaginal delivery may be safe.

Show evidence (2 references)

PMID:31671480 SUPPORT Human Clinical

"Women with placenta previa in the second trimester had a higher risk of a low-positioned placenta in the third trimester than did those with a low-lying placenta in the second trimester (37/181 (20.4%) vs 11/777 (1.4%); relative risk (RR), 17.9 (95% CI, 8.9-36.0))."

Quantifies the persistence difference between the two subtypes - an 18-fold relative risk - which is what makes them worth separating rather than grading.

PMID:16582134 SUPPORT Other

"Small studies suggest that, when the placenta to cervical os distance is greater than 2 cm, women may safely have a vaginal delivery."

Records the management consequence of the distinction, with the source's own hedge about study size.

?

Discussions and Knowledge Gaps

2

Does cervical remodelling cause the antepartum bleeding in placenta previa, or does it only mark the subset that bleeds catastrophically?

CONTROVERSY previa_cervical_remodelling_vs_severity_marker

Attached to

pathophysiology#Cervical Remodelling and Lower Segment Formation at the Placental Edge

The two cohorts cited on that node disagree, and they disagree in a way that matters for the mechanism rather than only for prediction. Ghi and colleagues (n=59, complete previa only) found cervical length significantly shorter in women needing emergency delivery for massive haemorrhage but not different between women who bled and women who did not - which would make cervical shortening a severity marker, not the cause of bleeding as such. Altraigey and colleagues (n=328, previa and/or accreta) found short cervix associated with antepartum haemorrhage itself. The cohorts differ in size, in case mix, and in whether accreta was included, so the discrepancy has an obvious candidate explanation and no resolving study is cited here. The textbook account - lower-segment formation shears an inelastic placenta off the decidua - is mechanically plausible and is what every review states, but no reference in this entry demonstrates the shearing event directly.

Why does the placenta implant low in the first place, and is a damaged endometrium really the reason?

KNOWLEDGE GAP previa_why_low_implantation

Attached to

pathophysiology#Endometrial and Decidual Damage at the Lower Uterine Segment pathophysiology#Low Implantation of the Blastocyst

The endometrial-damage account is inferred entirely from the direction of the risk factors. No human study observes the implantation event, so the first two nodes of this pathograph rest on epidemiology plus the scar-specific mechanism borrowed from placenta accreta spectrum. The strongest single risk factor - assisted reproductive technology, RR 3.71 - is also the one least well explained by endometrial damage, since embryo transfer places the blastocyst mechanically; and the endometriosis data show an effect independent of conception method, which the damage account predicts but does not uniquely explain. The alternative account, that a large placenta spreads into the lower segment secondary to relative hypoxaemia, is the usual explanation offered for the smoking association and is not tested against the damage account by anything cited here.

⚙

Pathophysiology

13

Endometrial and Decidual Damage at the Lower Uterine Segment

Every well-replicated risk factor for placenta previa - prior caesarean, uterine curettage after induced or spontaneous abortion, intrauterine surgery, endometriosis, advancing maternal age - is a cause of endometrial injury. The proposed common step is that injury alters decidualisation and drives excessive vascular remodelling, so the scarred region no longer supports normal implantation and the blastocyst implants elsewhere, including low in the uterus. This is a mechanism inferred from a consistent epidemiology rather than one demonstrated at the implantation site in humans, and it is recorded at that strength.

endometrial stromal cell CL:0002255 decidual cell CL:2000002

decidualization GO:0046697 ↓ DECREASED

endometrium UBERON:0001295

Downstream

Low Implantation of the Blastocyst The step from a damaged endometrium to a low implantation site is the weakest link in the chain. It is supported by the consistent direction of every risk factor and by the scar-specific version of the argument that holds for placenta accreta spectrum, but no human study observes the implantation event itself.

Show evidence (2 references)

PMID:23127895 SUPPORT Other

"These factors imply some degree of tissue damage, which can modify the decidualisation process, and produce excessive vascular remodelling."

States the decidualisation-damage mechanism linking the shared risk factors (induced labour, termination, caesarean, older age) to abnormal placentation.

PMID:34768164 SUPPORT Human Clinical

"smoking (OR 1·42, 95% CI 1·30, 1·54) (RR 1·27, 95% CI: 1·18, 1·35) advanced maternal age (OR 3·16, 95% CI: 2·79, 3·57), cesarean (OR 1·60, 95% CI: 1·44, 1·76) and ART (singleton pregnancy) (RR 3·71, 95% CI: 2·67, 5·16) were graded as highly suggestive evidence (class III)."

Umbrella review of nine meta-analyses grading the endometrial-injury risk factors at the highest evidence class it awards. Advanced maternal age carries the largest effect of the group.

Low Implantation of the Blastocyst

The blastocyst implants in the lower uterine segment rather than the fundus. This node is an inferred event, not an observed one - implantation site in a human pregnancy is reconstructed backwards from where the placenta is later seen.

embryo implantation GO:0007566

uterus UBERON:0000995

Downstream

Placental Development Overlying the Internal Cervical Os

The placenta develops over or beside the internal os. At this point the disorder is a position, not yet an injury: most pregnancies diagnosed here in the second trimester will resolve, and the ones that do not acquire their pathology from what the cervix and lower segment do next.

placenta UBERON:0001987 uterine cervix UBERON:0000002

Downstream

Failure of Trophotropic Migration Away from the Internal Os

Deficient Decidua Basalis Over the Uterine Scar This branch is taken only when the low implantation site coincides with a previous caesarean scar. A previa on unscarred myometrium does not take it, so the edge is conditional on the scar rather than obligatory.

Fetal Growth Restriction The lower segment is less well vascularised than the fundus, which predicts impaired fetal growth. The measured effect is real but small, and the pooled estimate is highly heterogeneous - so this edge is included as a weak one rather than as a core feature of the disease.

Show evidence (1 reference)

PMID:39654466 SUPPORT Other

"Today, placenta previa is typically identified during routine second-trimester ultrasound, with the overwhelming majority of cases resolving before term."

Establishes that the second-trimester finding is usually transient, which is why the entry treats persistence rather than presence as the pathological step.

Failure of Trophotropic Migration Away from the Internal Os

Placental migration is not movement. The placenta grows preferentially toward the better-vascularised fundus while the tissue lying over the poorly vascularised cervix and lower segment atrophies, so the placental edge retreats from the os at roughly 5 mm per week and the great majority of second-trimester diagnoses resolve. Persistent placenta previa is the failure of this process - which is the reason the disease is defined by a third-trimester finding and why a covering placenta and a merely low-lying one behave so differently. The same process, running to completion over a velamentous cord, is the accepted explanation for vasa previa: the placental tissue atrophies and leaves the fetal vessels behind.

placenta UBERON:0001987

Downstream

Persistent Placenta Previa in the Third Trimester

Show evidence (4 references)

PMID:37590981 SUPPORT Other

"It has been proposed that the placenta grows preferentially toward the better-vascularized fundus of the uterus with advancing gestational age, and then the placental tissue overlying the less well-vascularized cervix and lower uterine segment undergoes atrophy, leaving behind exposed fetal vessels."

The trophotropism mechanism, stated by the source as a proposal rather than an established fact - the hedge is preserved here. Quoted from the vasa previa literature because that is where the mechanism is articulated most explicitly.

PMID:38841031 SUPPORT Other

"Research suggests a migration rate of approximately 5.4 mm per week, with over 98.4% of suspected low-lying/placenta previa cases in the second trimester resolving before delivery, typically around 26 weeks of gestation, leaving only 1.6% persisting until term"

Quantifies both the rate of retreat and the proportion in which it succeeds.

PMID:35841836 REFUTE Human Clinical

"62.5% of the pregnant women with 28th-week placenta previa were still with previa at the 36 weeks of gestation (25.8% with marginal and 36.7% with partial/complete placenta previa)."

REFUTE against the general reading of the 98%-resolve figure above, not against the migration mechanism. The resolve rate is a statement about second-trimester findings; in 368 women whose previa had already persisted to 28 weeks, most did not resolve by 36 weeks. The two figures describe different starting points, and quoting only the first would misdescribe the natural history of an established previa.

+ 1 more reference

Persistent Placenta Previa in the Third Trimester

A placenta still overlying or abutting the internal os in the third trimester. A prior caesarean makes persistence markedly more likely, and a posterior placenta persists more often than an anterior one - so the same scarring that is thought to cause the low implantation also makes it less likely to resolve.

placenta UBERON:0001987

Downstream

Cervical Remodelling and Lower Segment Formation at the Placental Edge

Poorly Contractile Placental Bed in the Lower Uterine Segment

Obstruction of the Birth Canal

Show evidence (1 reference)

PMID:31671480 SUPPORT Human Clinical

"Women with a posterior placenta had a higher risk of a low-positioned placenta in the third trimester than did those with an anterior placenta (38/594 (6.4%) vs 10/364 (2.7%); RR, 2.4 (95% CI, 1.2-4.9)), as did women with a history of Cesarean section compared with those without such a history..."

Identifies prior caesarean and posterior position as predictors of persistence, with effect sizes.

Cervical Remodelling and Lower Segment Formation at the Placental Edge

As term approaches, the lower uterine segment forms and the cervix softens, shortens and effaces. The placenta cannot accommodate that change, so the utero-placental interface at the placental edge is disrupted. The clinical signature of this being a maternal-tissue event rather than a fetal one is that the bleeding is bright red, painless, and of maternal origin. The evidence that cervical change specifically drives the bleeding is mixed and is recorded that way: a short cervix predicts the severe, early, emergency-delivery haemorrhage, but in the same cohort it did not distinguish women who bled at all from those who did not.

uterine cervix UBERON:0000002 myometrium UBERON:0001296

Downstream

Maternal Sinus Haemorrhage from the Placental Bed

Show evidence (3 references)

PMID:19173235 SUPPORT INDIRECT Human Clinical

"was significantly shorter among patients who underwent emergency Cesarean section < 34 weeks due to massive hemorrhage compared with patients who underwent elective Cesarean section (29.4 +/- 5.7 mm vs. 38.8 +/- 8.5 mm; P = 0.0006)"

A 9 mm shorter cervix in the women who bled catastrophically. INDIRECT because cervical length is a marker of the remodelling process rather than a measurement of interface disruption.

PMID:19173235 REFUTE Human Clinical

"Cervical length did not differ significantly between cases with and those without prepartum bleeding (35.3 +/- 9.3 mm vs. 38.4 +/- 8.2 mm; P = 0.18)"

The same 59-woman cohort, and the reason this node is not asserted more strongly. Cervical length separated the severe cases but not bleeding as such. Kept as a REFUTE item against the general form of the claim rather than dropped.

PMID:31434519 SUPPORT Human Clinical

"Women with short cervix had significantly higher rates of preterm birth, antepartum hemorrhage, emergency cesarean sections, intraoperative estimated blood loss, massive bleeding, prevalence of placental adherence and cesarean hysterectomy"

A larger cohort (n=328) that does find the association with antepartum haemorrhage itself, not only with its severe form - which is why the disagreement above is recorded as unresolved rather than settled against the mechanism.

Maternal Sinus Haemorrhage from the Placental Bed

Disruption of the interface opens maternal venous sinuses in the placental bed, and blood escapes through the cervix. Because the bleeding is maternal and the uterus is not contracting against a retro-placental clot, it is painless - the single feature that distinguishes it at the bedside from placental abruption.

decidua basalis UBERON:0000453

Downstream

Antepartum Hemorrhage

Hypovolemic Shock

Indicated Preterm Delivery Bleeding is the proximate trigger for early delivery, so the haemorrhage arm and the prematurity arm are not independent complications - one causes the other.

Deficient Decidua Basalis Over the Uterine Scar

Where the low-implanting placenta lands on a caesarean scar, the scar has not re-epithelialised and the decidua basalis is absent or deficient. The decidua is the brake on extravillous trophoblast migration, so its absence permits otherwise normal placentation to proceed into the myometrium. This is the mechanism shared with the Placenta Accreta Spectrum entry, reached here from the previa side: it is why previa and prior caesarean multiply rather than merely add.

decidual cell CL:2000002

decidua basalis UBERON:0000453

Downstream

Unimpeded Extravillous Trophoblast Invasion of the Myometrium

Show evidence (3 references)

PMID:24338130 SUPPORT Human Clinical

"as were women with previa (adjusted odds ratio [OR], 34.9; 95% confidence interval [CI], 22.4-54.3)"

73,257 caesarean deliveries. A 35-fold adjusted odds ratio is the largest single risk factor for accreta in the cohort, which is why previa is treated here as a cause of PAS rather than a co-finding.

PMID:24338130 SUPPORT Human Clinical

"patients with previa and two or three prior cesarean deliveries had an adjusted OR for accreta of 4.9 (95% CI, 1.7-14.3) or 7.7 (95% CI, 2.4-24.9), respectively"

Within the previa group alone, risk scales with the number of scars - the dose-response that the deficient-decidua mechanism predicts.

PMID:28268196 SUPPORT Human Clinical

"The incidence of placenta previa accreta was 4.1% in women with 1 prior cesarean and 13.3% in women with ≥2 previous cesarean deliveries."

The same dose-response in a 3,889-pregnancy meta-analysis, as absolute incidences.

Unimpeded Extravillous Trophoblast Invasion of the Myometrium

Extravillous trophoblast migrates into the myometrium because the decidual barrier that normally limits it is not there. The sonographic correlate at the previa site is lower-segment hypervascularity and large, swirling placental lacunae, detectable as early as the first trimester.

extravillous trophoblast CL:0008036

trophoblast cell migration GO:0061450 ↑ INCREASED blood vessel remodeling GO:0001974 ↑ INCREASED

myometrium UBERON:0001296

Downstream

Failure of Placental Separation at Delivery

Show evidence (2 references)

PMID:34837427 SUPPORT Human Clinical

"Lower uterine segment (uterovesical, subplacental and/or intraplacental) hypervascularity was present in 14/14 (100%) cases and only 1/12 (8.3%) controls (P < 0.001)."

Case-control study in which both arms are low-implantation pregnancies, so the comparison isolates the invasion signal rather than the low position.

PMID:34837427 SUPPORT Human Clinical

"Placental lacunae were present in 18/21 (85.7%) cases and 7/46 (15.2%) controls (odds ratio (OR), 33.4; 95% CI, 7.7-144.4; P < 0.001)."

The lacunae marker in the same first-trimester low-implantation comparison.

Failure of Placental Separation at Delivery

Villi anchored in the myometrium cannot shear off at the decidual plane, so the third stage does not complete. Attempting to remove the placenta tears the myometrium and opens the invaded vasculature - which is why the standard of care is to leave it alone and proceed to hysterectomy.

myometrium UBERON:0001296

Downstream

Post-partum Hemorrhage

Show evidence (1 reference)

PMID:16582134 SUPPORT Other

"Women known to have placenta accreta should be delivered by cesarean, and no attempt should be made to separate the placenta at the time of delivery."

The management rule follows from the mechanism: separation is not achievable, so attempting it converts a controlled delivery into a haemorrhage.

Poorly Contractile Placental Bed in the Lower Uterine Segment

After any delivery, haemostasis at the placental bed is mechanical: myometrial contraction occludes the spiral arteries. The lower uterine segment is a poorly contractile part of the uterus, so a placental bed sited there does not get that closure, and the newly formed vessels of the abnormally remodelled bed keep bleeding. This is why postpartum haemorrhage in previa happens even when the placenta separates normally and there is no accreta - it is a separate mechanism from the one above, converging on the same phenotype.

myometrium UBERON:0001296

Downstream

Post-partum Hemorrhage

Show evidence (1 reference)

PMID:23127895 SUPPORT Other

"Placenta praevia and accreta are mainly located in the lower segment, a place that predisposes to persistent uterine bleeding because of the development of new vessels and because it is a poorly contractile area of the uterus."

States both components of this node - neovascularisation and the contractile deficit of the lower segment - as the reason bleeding persists after delivery.

Obstruction of the Birth Canal

The placenta lies between the fetus and the cervix. Labour would deliver the placenta first, detaching the fetal circulation before the fetus is born, so vaginal delivery is not available and abdominal delivery is obligatory rather than merely preferred. A low-lying placenta more than 2 cm from the os is the exception.

uterine cervix UBERON:0000002

Downstream

Indicated Preterm Delivery

Show evidence (1 reference)

PMID:16582134 SUPPORT Other

"The diagnostic modality of choice for placenta previa is transvaginal ultrasonography, and women with a complete placenta previa should be delivered by cesarean."

States the obligate abdominal route for a covering placenta.

Indicated Preterm Delivery

Delivery is scheduled before term to pre-empt catastrophic haemorrhage, or happens as an emergency when haemorrhage occurs. Either way prematurity in placenta previa is substantially iatrogenic and deliberate - a chosen trade of neonatal risk against maternal risk - which is a different thing from spontaneous preterm labour and is the reason antenatal corticosteroids are a mainstay.

Downstream

Premature Birth

Neonatal Death Mediated by the recognised complications of prematurity - respiratory distress syndrome, low birth weight and birth asphyxia - rather than by the placental position acting on the fetus directly.

Show evidence (2 references)

PMID:38841031 SUPPORT Other

"Preterm birth emerges as a prevalent complication linked to placenta previa, with approximately 5% of all preterm deliveries attributed to this condition"

Gives the population-level contribution of previa to preterm birth, which is large relative to the condition's 0.5% prevalence.

PMID:38841031 SUPPORT Other

"for uncomplicated complete placenta previa, scheduling delivery between 36 and 37 weeks is advisable"

Documents that the timing is planned rather than spontaneous, supporting the iatrogenic framing of this node.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

6

Blood 2

Antepartum Hemorrhage FREQUENT HP:0025328

Temporal: RECURRENT

Show evidence (2 references)

PMID:19173235 SUPPORT Human Clinical

"Twenty-nine (49.1%) of the women presented prepartum bleeding and 12 (20.3%) required an emergency Cesarean section prior to 34 completed weeks due to massive hemorrhage."

Gives the frequency in a cohort restricted to complete previa persisting into the third trimester, which is the population this frequency band is about.

PMID:38841031 SUPPORT Other

"Placenta previa stands as a primary cause of third-trimester hemorrhage and manifests through painless bleeding, posing life-threatening risks for both the mother and the infant"

Establishes the painless character of the bleeding.

Post-partum Hemorrhage HP:0011891

Show evidence (1 reference)

PMID:40188841 SUPPORT Human Clinical

"Risk factors with a strong association with postpartum haemorrhage included anaemia, previous postpartum haemorrhage, caesarean birth, female genital mutilation, sepsis, no antenatal care, multiple pregnancy, placenta praevia, assisted reproductive technology use, macrosomia with a birthweight..."

Places placenta praevia in the highest association tier the review defines (pooled OR greater than 2).

Cardiovascular 1

Hypovolemic Shock HP:0031274

Temporal: ACUTE

Show evidence (1 reference)

PMID:19173235 SUPPORT INDIRECT Human Clinical

"Twenty-nine (49.1%) of the women presented prepartum bleeding and 12 (20.3%) required an emergency Cesarean section prior to 34 completed weeks due to massive hemorrhage."

INDIRECT because the cohort reports emergency delivery for massive haemorrhage rather than measured haemodynamic shock, so the phenotype is inferred from the intervention it prompted.

Prenatal and Birth 1

Premature Birth FREQUENT HP:0001622

Show evidence (1 reference)

PMID:38841031 SUPPORT Other

"Preterm birth emerges as a prevalent complication linked to placenta previa, with approximately 5% of all preterm deliveries attributed to this condition"

Quantifies previa's share of the population burden of preterm birth.

Growth 1

Fetal Growth Restriction OCCASIONAL Intrauterine growth retardation HP:0001511

Show evidence (1 reference)

PMID:31301678 SUPPORT Human Clinical

"The incidence of growth abnormalities was 8.7/100 births in cases of placenta previa vs. 5.8/100 births among controls."

Absolute incidences behind the pooled odds ratio, which is what the OCCASIONAL band is set from.

Other 1

Neonatal Death VERY_RARE

Deliberately left unbound. HPO has a term - HP:0003811 Neonatal death - but it sits under Mortality/Aging rather than under HP:0000118 phenotypic abnormality, so it is outside the PhenotypeTerm dynamic-enum root and binding it fails term validation. This is the same enum-root gap that issue #7837 records for HP:0003826 Stillbirth, HP:0009800 Maternal diabetes and HP:0100602 Preeclampsia; Intrahepatic Cholestasis of Pregnancy leaves its stillbirth phenotype unbound for the same reason. Recorded here as a fourth instance rather than worked around.

Show evidence (1 reference)

PMID:38841031 SUPPORT Other

"a study revealed a neonatal mortality rate of 10.7 per 1,000 births in previa cases, contrasting with 2.5 per 1,000 in other pregnancies (relative risk: 4.3; 95% confidence interval: 4.0, 4.8)"

10.7 per 1000 is about 1%, which sets the VERY_RARE frequency band even though the relative risk is fourfold.

💊

Medical Actions

9

Planned Cesarean Delivery

Action: cesarean delivery Ontology label: Cesarean Section NCIT:C46088

Platform: Surgery

The definitive management, and the intervention that turned placenta previa from a major cause of maternal death into a manageable condition. A covering placenta mandates it; a low-lying placenta more than 2 cm from the os may allow a trial of vaginal delivery. Scheduling is a deliberate trade: 36-37 weeks for an uncomplicated complete previa balances the bleeding risk of waiting against the neonatal risk of delivering early. Delivery should be at an institution able to transfuse.

Mechanism Target:

Obstruction of the Birth Canal — Bypasses the obstruction rather than correcting it - the placental position is unchanged, the fetus simply does not have to pass it.

Cervical Remodelling and Lower Segment Formation at the Placental Edge — Pre-empting labour prevents the cervical change that disrupts the interface, which is why scheduled delivery is the whole strategy rather than a fallback.

Show evidence (3 references)

PMID:39654466 SUPPORT Other

"A planned cesarean delivery is recommended in cases that persist into the late third trimester."

States the recommendation for the persistent case, which is the treated population.

PMID:38841031 SUPPORT Other

"for uncomplicated complete placenta previa, scheduling delivery between 36 and 37 weeks is advisable"

Gives the timing and the reasoning behind it.

PMID:16582134 SUPPORT Other

"Delivery should take place at an institution with adequate blood banking facilities."

Records the setting requirement, which follows from the haemorrhage risk.

Antenatal Corticosteroid Therapy

Action: antenatal corticosteroid administration Ontology label: Systemic Corticosteroid Therapy NCIT:C122080

Agent: betamethasone CHEBI:3077

Platform: Small molecule

Given because delivery in placenta previa is expected to be preterm. It targets the consequence of the obstetric decision rather than the placental disorder - the clearest example in this entry of a treatment aimed at an iatrogenic arm of the pathograph.

Mechanism Target:

Indicated Preterm Delivery — Mitigates the neonatal consequences of early delivery; it does not reduce the likelihood of early delivery.

Show evidence (1 reference)

PMID:38841031 SUPPORT Other

"ACS has since demonstrated a capacity to decrease the risk of late miscarriages, infant deaths, RDS, intraventricular hemorrhage, necrotizing enterocolitis, and systemic infections within the first two days of life"

Summarises the neonatal benefit of antenatal corticosteroids. Note this is the general preterm-birth evidence base, not a previa-specific trial.

Blood Transfusion and Haemorrhage Support

Action: blood transfusion Ontology label: Blood Transfusion NCIT:C15192

Supportive rather than mechanistic: replaces what is lost while the bleeding source is addressed surgically. Its availability is a precondition for delivering a previa safely rather than an optional adjunct.

Mechanism Target:

Hypovolemic Shock — Restores circulating volume and oxygen-carrying capacity.

Show evidence (1 reference)

PMID:16582134 SUPPORT Other

"Delivery should take place at an institution with adequate blood banking facilities."

Establishes transfusion capacity as a requirement of the delivery plan.

Uterotonic Therapy

Action: uterotonic pharmacotherapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: oxytocin CHEBI:7872 misoprostol CHEBI:63610

First pharmacological step once the placenta is delivered and the bed is bleeding. Oxytocin and the prostaglandin analogue misoprostol drive myometrial contraction to close the spiral arteries mechanically. The important qualification in previa is that the bleeding bed is the lower uterine segment, which is thin and comparatively fibrous, so it contracts poorly by comparison with the fundus; uterotonics therefore work less well here than in atonic post-partum haemorrhage from a normally sited placenta, and are the first rung of an escalation ladder rather than a definitive answer. This entry records the intervention and its mechanism; no efficacy figure is recorded because the cited trial registration carries no results.

Mechanism Target:

INHIBITS Poorly Contractile Placental Bed in the Lower Uterine Segment — Stimulates myometrial contraction to compress the open sinuses. Effect is limited by the very property this node names - the lower segment contracts poorly - which is why the ladder continues past this step.

INHIBITS Post-partum Hemorrhage — Reduces blood loss by achieving mechanical haemostasis at the placental bed.

Show evidence (1 reference)

clinicaltrials:NCT05340205 SUPPORT Other

"To compare the efficacy and safety profile of intravenous tranexamic acid versus intrauterine misoprostol in reducing the blood loss during and after cesarean delivery in pregnant women diagnosed with placenta previa"

Registration record establishing that intrauterine misoprostol is used to reduce blood loss at caesarean delivery specifically in placenta previa. Graded OTHER because a trial registration is a design document, not a reported study result; the registry carries no outcome values, so no efficacy claim is made here.

Tranexamic Acid

Action: antifibrinolytic pharmacotherapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: tranexamic acid CHEBI:48669

Platform: Small molecule

Antifibrinolytic given to limit clot breakdown at the bleeding placental bed. It acts on the haemostatic arm rather than the contractile one, which is what makes it complementary to uterotonics in a bed that contracts poorly - the mechanism does not depend on the myometrium. Used peri-operatively at caesarean delivery in previa.

Mechanism Target:

INHIBITS Maternal Sinus Haemorrhage from the Placental Bed — Inhibits fibrinolysis so that clot formed over the open maternal sinuses is not broken down, acting independently of myometrial contraction.

INHIBITS Post-partum Hemorrhage — Reduces total blood loss during and after caesarean delivery.

Show evidence (1 reference)

clinicaltrials:NCT05340205 SUPPORT Other

"To compare the efficacy and safety profile of intravenous tranexamic acid versus intrauterine misoprostol in reducing the blood loss during and after cesarean delivery in pregnant women diagnosed with placenta previa"

Registration record establishing intravenous tranexamic acid as a blood-loss reducing intervention at caesarean delivery in placenta previa. Graded OTHER as a design document; the registry reports no outcome values, so efficacy is not claimed.

Intrauterine Balloon Tamponade

Action: intrauterine balloon tamponade Ontology label: Therapeutic Procedure NCIT:C49236

Platform: Device

Mechanical second-line measure: a balloon catheter inflated in the uterine cavity applies direct pressure to the bleeding lower-segment bed. Because it substitutes externally applied pressure for myometrial contraction, it addresses the specific failure mode of previa haemorrhage rather than depending on it, and it is explicitly a uterus-preserving alternative to hysterectomy.

Mechanism Target:

BYPASSES Poorly Contractile Placental Bed in the Lower Uterine Segment — Supplies mechanical compression from within the cavity, working around the poor contractility of the lower segment instead of trying to correct it.

INHIBITS Maternal Sinus Haemorrhage from the Placental Bed — Direct pressure closes the open maternal sinuses.

Show evidence (3 references)

PMID:38841031 SUPPORT REVIEW SYNTHESIS Other

"Conservative management involves prophylactic double bilateral ligation of uterine arteries before placental removal, followed by tamponade using a saline-filled balloon catheter"

Places balloon tamponade in the conservative-management arm for placenta previa. Graded OTHER with quote_role REVIEW_SYNTHESIS because the sentence is this review's summary of reference [38] rather than its own observation.

PMID:38841031 SUPPORT REVIEW SYNTHESIS Other

"This strategy aims to circumvent hysterectomy and safeguard the patient's future fertility"

Sources the stated purpose of the conservative arm - uterine preservation.

clinicaltrials:NCT05133167 SUPPORT Other

"In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage."

Registration record for a completed previa-specific randomized trial, establishing the intra-operative use of Foley-balloon tamponade. Cited for design, not efficacy - the registry carries no outcome values.

Uterine Compression Sutures

Action: uterine compression suture placement Ontology label: Surgical Procedure NCIT:C15329

Platform: Surgery

Surgical apposition of the uterine walls (B-Lynch or parallel vertical compression sutures) to compress the bleeding bed, used intra-operatively at caesarean when pharmacological measures have not controlled the loss. Like tamponade, it is a uterus-preserving step taken before hysterectomy is accepted.

Mechanism Target:

BYPASSES Poorly Contractile Placental Bed in the Lower Uterine Segment — Externally applied surgical compression substitutes for the contraction the lower segment cannot generate.

INHIBITS Post-partum Hemorrhage — Controls ongoing intra-operative blood loss short of hysterectomy.

Show evidence (2 references)

PMID:38841031 SUPPORT REVIEW SYNTHESIS Other

"Other hemorrhage control measures may include B-Lynch or parallel vertical compression sutures, uterine artery ligation (O'Leary stitch), and aortic balloon occlusion before C-HYST"

Names compression sutures among the haemorrhage-control measures used before caesarean hysterectomy is accepted. Graded OTHER with quote_role REVIEW_SYNTHESIS - the sentence is the review's synthesis of reference [40].

clinicaltrials:NCT05133167 SUPPORT Other

"In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage."

Registration record establishing intra-operative B-Lynch suture use in placenta previa. Cited for design only; no outcome values are registered.

Pelvic Arterial Embolization

Action: pelvic arterial embolization Ontology label: Arterial Embolization NCIT:C15917

Interventional-radiology control of the uterine and pelvic arterial supply, either as pre-delivery catheter placement in anticipated accreta spectrum or as rescue when bleeding continues. It acts on arterial inflow rather than on the myometrium, and is the last uterus-preserving rung before hysterectomy.

Mechanism Target:

INHIBITS Maternal Sinus Haemorrhage from the Placental Bed — Occludes the arterial supply feeding the placental bed, reducing inflow to the open maternal sinuses.

Show evidence (1 reference)

PMID:38841031 SUPPORT REVIEW SYNTHESIS Other

"interventions such as balloon catheters for angiographic embolization of pelvic vessels and aortic balloon occlusion preceding cesarean hysterectomy (C-HYST) deployed to mitigate hemorrhage"

Establishes angiographic embolization of pelvic vessels as a blood-loss control measure in this setting. Graded OTHER with quote_role REVIEW_SYNTHESIS as the review's restatement of reference [19].

Peripartum Hysterectomy

Action: peripartum hysterectomy Ontology label: Hysterectomy NCIT:C15256

Platform: Surgery

The endpoint when the placenta cannot be separated, which in practice means when accreta spectrum is superimposed on the previa. It is a definitive haemostatic operation and an irreversible one; the great majority of significant accreta cases need it.

Mechanism Target:

Failure of Placental Separation at Delivery — Removes the uterus with the placenta in situ, so the un-separable interface is never disturbed.

Poorly Contractile Placental Bed in the Lower Uterine Segment — Also removes the bleeding bed itself, which is why it works when uterotonics - which depend on a contractile myometrium - do not.

Show evidence (2 references)

PMID:16582134 SUPPORT Other

"The majority of women with significant degrees of placenta accreta will require a hysterectomy."

States the frequency with which the definitive operation is needed.

PMID:16582134 NO_EVIDENCE Other

"Although successful conservative management has been described, there are currently insufficient data to recommend this approach to management routinely."

Recorded as NO_EVIDENCE for the uterus-preserving alternative: the source reports it exists and explicitly declines to judge it, which is not support either way.

🌍

Environmental Factors

3

Maternal Cigarette Smoking

Smoking in pregnancy raises previa risk by about 40%. The usual proposed mechanism is that carbon-monoxide-mediated relative hypoxaemia drives compensatory placental enlargement, so the placenta spreads far enough to reach the lower segment - but the cited evidence is epidemiological and identifies no mediating step, so the link is recorded as an association with an unestablished mechanism.

Show evidence (1 reference)

PMID:34768164 SUPPORT Human Clinical

"smoking (OR 1·42, 95% CI 1·30, 1·54) (RR 1·27, 95% CI: 1·18, 1·35) advanced maternal age (OR 3·16, 95% CI: 2·79, 3·57), cesarean (OR 1·60, 95% CI: 1·44, 1·76) and ART (singleton pregnancy) (RR 3·71, 95% CI: 2·67, 5·16) were graded as highly suggestive evidence (class III)."

The umbrella review grades smoking at its highest awarded evidence class, alongside the other established risk factors.

Mechanism Target:

PREDISPOSES Placental Development Overlying the Internal Cervical Os — A consistent, modest association with no demonstrated intermediate. Included because smoking is the main modifiable risk factor in the set, not because the mechanism is established.

Show evidence (1 reference)

PMID:27936997 SUPPORT Human Clinical

"compared to nonsmoker women, the estimated OR and RR of placenta previa was 1.42 (95% CI: 1.30, 1.54) and 1.27 (95% CI: 1.18, 1.35), respectively"

Meta-analysis over 9,094,443 participants giving both the odds-ratio and relative-risk forms of the association.

Endometriosis

Endometriosis nearly triples the risk of placenta previa, and the effect is strongly dose-dependent on disease severity - roughly sevenfold for revised-ASRM stage III-IV disease and fourteenfold for deep endometriosis. Critically, the association holds regardless of whether conception was assisted, which separates it from the ART-related risk and points at the endometrium itself rather than at the procedures.

Show evidence (1 reference)

PMID:39049473 SUPPORT Human Clinical

"We showed a higher risk of placenta previa in women with endometriosis compared to controls (34 studies, OR 2.84; 95% CI: 2.47, 3.26; I2 = 83%, moderate quality)"

The headline pooled association across 34 studies, graded moderate quality by GRADE.

Mechanism Target:

PREDISPOSES Endometrial and Decidual Damage at the Lower Uterine Segment — The severity gradient is the informative part: a risk factor whose effect scales with how much endometrial and pelvic disease is present is consistent with the decidualisation-damage node, though the study measures outcome rather than decidualisation.

Show evidence (1 reference)

PMID:39049473 SUPPORT INDIRECT Human Clinical

"The association was observed regardless of the method of conception and was particularly strong in the most severe forms of endometriosis (i.e. rASRM stage III-IV endometriosis and deep endometriosis (DE)) (OR 6.61; 95% CI: 2.08, 20.98; I2 = 66% and OR 14.54; 95% CI: 3.67, 57.67; I2 = 54%, respectively)"

Establishes both the independence from conception method and the severity gradient. INDIRECT because the inference from worse endometrial disease to the decidualisation node is a step the study does not take.

Assisted Reproductive Technology

ART in a singleton pregnancy carries a nearly fourfold relative risk of placenta previa - the largest effect among the established risk factors. Whether this is the technology, the underlying subfertility, or the endometrial pathology that caused the subfertility is unresolved; the endometriosis data above show that at least one component is independent of the method of conception.

Show evidence (2 references)

PMID:34768164 SUPPORT Human Clinical

"This study provides suggestive evidence about prior spontaneous abortion, prior induced abortion, male fetus, smoking, advanced maternal age, cesarean section, and assisted reproductive techniques (singleton pregnancy) as risk factors associated with placenta previa."

The umbrella review's own summary statement, listing assisted reproductive techniques among the risk factors it grades at class III.

PMID:26244528 SUPPORT Other

"the rates of previa and accreta are increasing, probably as a result of increasing rates of cesarean delivery, maternal age, and assisted reproductive technology"

Attributes the secular rise in previa incidence partly to ART uptake, which is the population-level reason this exposure matters rather than only the per-pregnancy relative risk.

Mechanism Target:

PREDISPOSES Low Implantation of the Blastocyst — Embryo transfer places the blastocyst mechanically rather than letting it implant where it arrives, which is an obvious candidate mechanism for an altered implantation site - but it is a hypothesis, and the cited evidence does not test it.

Show evidence (1 reference)

PMID:34768164 SUPPORT INDIRECT Human Clinical

"smoking (OR 1·42, 95% CI 1·30, 1·54) (RR 1·27, 95% CI: 1·18, 1·35) advanced maternal age (OR 3·16, 95% CI: 2·79, 3·57), cesarean (OR 1·60, 95% CI: 1·44, 1·76) and ART (singleton pregnancy) (RR 3·71, 95% CI: 2·67, 5·16) were graded as highly suggestive evidence (class III)."

Gives the ART effect size (RR 3.71) at the review's highest evidence class. INDIRECT because nothing in the quote bears on the implantation-site step.

🔬

Diagnosis

2

Transvaginal Ultrasonography

The diagnostic standard. Transvaginal scanning measures the placental edge to internal-os distance directly. Diagnosis is made in the third trimester, because a second-trimester finding usually resolves.

transvaginal ultrasound NCIT:C17644

Show evidence (2 references)

PMID:16582134 SUPPORT Other

"The diagnostic modality of choice for placenta previa is transvaginal ultrasonography, and women with a complete placenta previa should be delivered by cesarean."

Names transvaginal ultrasonography as the modality of choice.

PMID:31671480 SUPPORT Human Clinical

"Low-positioned placenta included placenta previa, defined as a placenta covering the internal os of the cervix, and a low-lying placenta, defined as a placenta lying near to (within 20 mm) but not overlying the internal os."

Gives the measured criteria the scan applies.

Assessment for Placenta Accreta Spectrum

A diagnosis of previa is also an indication to look for PAS, because roughly one in nine previas has it and the management differs completely. Lower-segment hypervascularity, placental lacunae and loss of the clear zone are assessable from the first trimester in a low-implantation pregnancy.

fetal ultrasound imaging NCIT:C222238

Show evidence (2 references)

PMID:39654466 SUPPORT Other

"When placenta previa is diagnosed, it is essential to assess for associated conditions like placenta accreta and vasa previa."

States the obligation to screen for PAS and vasa previa once previa is found.

PMID:34837427 SUPPORT Human Clinical

"In women at risk of PAS, ultrasound markers of PAS can and should be assessed as early as in the first trimester."

Supports first-trimester rather than third-trimester assessment in this population.

📊

Prevalence

3

Worldwide

Point Prevalence 520.0 per 100,000 (450.0–590.0) >1 in 1,000

5.2 per 1000 pregnancies. The denominator is pregnancies, not the general population, so this is a per-pregnancy occurrence rate and is not comparable with a population prevalence.

Show evidence (1 reference)

PMID:23551357 SUPPORT Human Clinical

"The overall prevalence of placenta praevia was 5.2 per 1000 pregnancies (95% CI: 4.5-5.9)."

Pooled worldwide per-pregnancy prevalence with its confidence interval.

Asia

Point Prevalence 1220.0 per 100,000 (950.0–1520.0) >1 in 1,000

12.2 per 1000 pregnancies, roughly four times the North American estimate. The source is explicit that it cannot tell whether this reflects true ethnic differences or unmeasured confounding, so it is recorded as a regional estimate and not as an ancestry effect.

Show evidence (2 references)

PMID:23551357 SUPPORT Human Clinical

"prevalence was highest among Asian studies (12.2 per 1000 pregnancies; 95% CI: 9.5-15.2) and lower among studies from Europe (3.6 per 1000 pregnancies; 95% CI: 2.8-4.6), North America (2.9 per 1000 pregnancies; 95% CI: 2.3-3.5) and Sub-Saharan Africa (2.7 per 1000 pregnancies; 95% CI: 0.3-11.0)."

Gives the regional breakdown; the same sentence carries the European and North American figures.

PMID:23551357 NO_EVIDENCE Human Clinical

"There is some evidence suggestive of regional variation in its prevalence, but it is not possible to determine from existing data whether this is due to true ethnic differences or other unknown factor(s)."

Recorded as NO_EVIDENCE against any causal reading of the regional difference: the authors state their data cannot distinguish ethnicity from other factors.

Pregnancies already complicated by a placenta previa (pooled cohorts)

Point Prevalence 11100.0 per 100,000 (7650.0–17350.0) >1 in 1,000

The conditional rate of placenta accreta spectrum given placenta previa - 11.1%, IQR 7.65-17.35 - not a population figure. It is recorded here because it is the number that governs how a previa is managed.

Show evidence (1 reference)

PMID:31722942 SUPPORT Human Clinical

"The incidence of PAS in women with a placenta previa was 11.10% (IQR 7.65-17.35)."

Pooled conditional incidence of PAS among women with placenta previa.

⚖️

Clinical Burden

High

Placenta previa is a leading cause of bleeding in the second half of pregnancy and of massive obstetric haemorrhage at delivery, and it sits in the top tier of risk factors for postpartum haemorrhage in the pooled literature. Perinatal loss is mediated almost entirely through preterm delivery rather than any direct fetal insult, with neonatal mortality running roughly four times the background rate.

Show evidence (3 references)

PMID:38841031 SUPPORT Other

"Placenta previa stands as a primary cause of third-trimester hemorrhage and manifests through painless bleeding, posing life-threatening risks for both the mother and the infant"

States the burden and the characteristic painless presentation.

PMID:40188841 SUPPORT Human Clinical

"Risk factors with a strong association with postpartum haemorrhage included anaemia, previous postpartum haemorrhage, caesarean birth, female genital mutilation, sepsis, no antenatal care, multiple pregnancy, placenta praevia, assisted reproductive technology use, macrosomia with a birthweight..."

Places placenta praevia in the strong-association tier (pooled OR above 2) for postpartum haemorrhage across 327 studies and 847 million women.

PMID:38841031 SUPPORT Other

"a study revealed a neonatal mortality rate of 10.7 per 1,000 births in previa cases, contrasting with 2.5 per 1,000 in other pregnancies (relative risk: 4.3; 95% confidence interval: 4.0, 4.8)"

Quantifies the excess neonatal mortality relative to pregnancies without previa.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Placenta Previa:

Placental Abruption

Overlapping Features The other major cause of second-half antepartum haemorrhage, and the one the painlessness of previa is meant to exclude. Curated separately.

Distinguishing Features

Abruption bleeds with pain and uterine tenderness because blood accumulates behind an attached placenta; previa bleeds painlessly because the blood escapes freely through the cervix.
Ultrasound localises the placenta away from the internal os in abruption, and abruption is a clinical rather than a sonographic diagnosis.

Show evidence (2 references)

PMID:17012465 SUPPORT Other

"Placental abruption complicates about 1% of pregnancies and is a leading cause of vaginal bleeding in the latter half of pregnancy."

Establishes abruption as the competing cause of second-half bleeding, at roughly twice the occurrence rate of previa, which is what makes it the differential that matters most at presentation.

PMID:17012465 SUPPORT Other

"The diagnosis of abruption is a clinical one, and ultrasonography and the Kleihauer-Betke test are of limited value."

The asymmetry that decides the differential: previa is diagnosed by transvaginal ultrasound, abruption clinically. A scan that localises the placenta away from the os therefore excludes previa without excluding abruption.

Vasa Previa

Overlapping Features Fetal rather than maternal vessels crossing the os, most often arising when a second-trimester previa resolves and leaves velamentous vessels behind - so the two conditions share the trophotropic mechanism of this entry's migration node and are not merely look-alikes. Not currently a dismech entry.

Distinguishing Features

The bleeding is fetal and small in volume but rapidly lethal to the fetus, whereas previa bleeding is maternal and threatens the mother.
Colour Doppler shows fetal vessels crossing over the cervix with no overlying placental tissue.

Show evidence (2 references)

PMID:37590981 SUPPORT Other

"Vasa previa refers to fetal vessels (arterial or venous) unprotected by placental tissue or umbilical cord running through the membranes over or in close proximity to the internal cervical os."

The definition that separates the two: the same anatomical location, but fetal vessels without placental tissue rather than placental tissue itself.

PMID:37590981 SUPPORT Other

"It has been proposed that the placenta grows preferentially toward the better-vascularized fundus of the uterus with advancing gestational age, and then the placental tissue overlying the less well-vascularized cervix and lower uterine segment undergoes atrophy, leaving behind exposed fetal vessels."

Why this is a mechanistic relative and not just a look-alike: the proposed origin of vasa previa is this entry's own migration node running to completion over a velamentous cord.

Placenta Accreta Spectrum

Overlapping Features Not an alternative diagnosis so much as a frequent superimposition - about one previa in nine. Curated separately.

Distinguishing Features

Distinguished antenatally by lower-segment hypervascularity, placental lacunae with swirling flow, and loss of the clear zone.
Distinguished at delivery by failure of the placenta to separate; a previa without those markers separates normally.

Show evidence (2 references)

PMID:31722942 SUPPORT Human Clinical

"The incidence of PAS in women with a placenta previa was 11.10% (IQR 7.65-17.35)."

Quantifies the overlap, which is why PAS is framed here as a superimposition to be actively excluded rather than an alternative diagnosis.

PMID:34837427 SUPPORT Human Clinical

"Lower uterine segment (uterovesical, subplacental and/or intraplacental) hypervascularity was present in 14/14 (100%) cases and only 1/12 (8.3%) controls (P < 0.001)."

The discriminating marker, measured in a study whose controls are themselves persistent previas without PAS - which is exactly the comparison this differential requires.

🔬

Clinical Trials

2

NCT05133167 NOT_APPLICABLE COMPLETED

Randomized open-label trial (n=60, Pakistan) comparing Foley-balloon tamponade with B-Lynch compression suture for prevention of post-partum haemorrhage in placenta previa, with 24-hour blood loss as the primary endpoint. Recorded for the two uterus-preserving interventions it tests head to head; the registry carries no result values, so no efficacy comparison is drawn.

Target Phenotypes: Post-partum hemorrhage HP:0011891

Show evidence (1 reference)

clinicaltrials:NCT05133167 SUPPORT Other

"In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage."

Registration record describing both arms. Graded OTHER because a registration is a design document rather than a reported result.

NCT05340205 PHASE_IV COMPLETED

Completed phase 4 randomized open-label trial (n=81, Cairo University) comparing intravenous tranexamic acid with intrauterine misoprostol for reduction of blood loss during and after caesarean delivery in placenta previa. Recorded for the pharmacological arms of the escalation ladder; the registry holds no outcome values, so it is cited for design only.

Target Phenotypes: Post-partum hemorrhage HP:0011891

Show evidence (1 reference)

clinicaltrials:NCT05340205 SUPPORT Other

"To compare the efficacy and safety profile of intravenous tranexamic acid versus intrauterine misoprostol in reducing the blood loss during and after cesarean delivery in pregnant women diagnosed with placenta previa"

Registration record stating both pharmacological arms and the population. Graded OTHER as a design document with no registered results.

{ }

Source YAML

click to show

name: Placenta Previa
creation_date: "2026-09-15T00:00:00Z"
category: Complex
synonyms:
- Placenta praevia
- Low-lying placenta
- Praevia
description: >-
  Placenta previa is a disorder of placental implantation site, not of placental
  function: the placenta develops over or beside the internal cervical os instead of
  in the fundus, so the organ that must stay attached until after delivery sits on the
  one part of the uterus that has to open first. Almost everything clinically
  important follows from that single geometric fact. Low implantation is favoured by
  endometrial and decidual damage - prior caesarean, curettage, uterine surgery,
  endometriosis - which is thought to impair decidualisation at the usual fundal site.
  The great majority of second-trimester diagnoses then resolve, because the placenta
  grows preferentially toward the better-vascularised fundus while the tissue over the
  cervix atrophies; persistence is failure of that trophotropic migration rather than
  a separate disease. In the pregnancies where it persists, cervical remodelling and
  lower-segment formation disrupt the utero-placental interface and open maternal
  venous sinuses, producing the classic painless bright-red antepartum haemorrhage;
  the placenta blocks the birth canal, forcing abdominal delivery, usually preterm;
  and after delivery the placental bed lies in the lower segment, which is a poorly
  contractile part of the uterus, so the mechanical haemostasis that normally closes
  the bed does not happen. Where the low implantation lands on a caesarean scar, the
  decidua basalis is deficient and placenta accreta spectrum is superimposed - which
  is why previa is by a wide margin the strongest risk factor for PAS rather than
  merely a co-occurring finding.
disease_term:
  preferred_term: placenta praevia
  term:
    id: MONDO:0005918
    label: placenta praevia
parents:
- Placenta disorder
- Obstetric disorder
classifications:
  harrisons_chapter:
  - classification_value: OTHER
references:
- reference: PMID:39654466
  title: Placenta Previa.
- reference: PMID:32591150
  title: "Guideline No. 402: Diagnosis and Management of Placenta Previa."
has_subtypes:
- name: Previa
  display_name: Placenta previa (placenta covering the internal cervical os)
  description: >-
    The placental edge overlies the internal os. This is the form that persists into
    the third trimester far more often than a merely low-lying placenta does, and it
    is the form that mandates abdominal delivery.
  evidence:
  - reference: PMID:31671480
    reference_title: "Follow-up ultrasound in second-trimester low-positioned anterior and posterior placentae: prospective cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Low-positioned placenta included placenta previa, defined as a placenta covering the internal os of the cervix, and a low-lying placenta, defined as a placenta lying near to (within 20 mm) but not overlying the internal os."
    explanation: States the covering-versus-near definition that separates the two contemporary subtypes.
- name: Low-Lying
  display_name: Low-lying placenta (edge within 20 mm of the internal os, not covering)
  description: >-
    The placental edge lies within 20 mm of the internal os without overlying it. It
    is worth separating rather than treating as a milder grade of the same thing: in
    the second trimester it persists to the third in about 1 in 70 cases against 1 in 5
    for a covering placenta, and above a 2 cm placenta-to-os distance vaginal delivery
    may be safe.
  evidence:
  - reference: PMID:31671480
    reference_title: "Follow-up ultrasound in second-trimester low-positioned anterior and posterior placentae: prospective cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Women with placenta previa in the second trimester had a higher risk of a low-positioned placenta in the third trimester than did those with a low-lying placenta in the second trimester (37/181 (20.4%) vs 11/777 (1.4%); relative risk (RR), 17.9 (95% CI, 8.9-36.0))."
    explanation: >-
      Quantifies the persistence difference between the two subtypes - an 18-fold
      relative risk - which is what makes them worth separating rather than grading.
  - reference: PMID:16582134
    reference_title: "Placenta previa, placenta accreta, and vasa previa."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Small studies suggest that, when the placenta to cervical os distance is greater than 2 cm, women may safely have a vaginal delivery."
    explanation: Records the management consequence of the distinction, with the source's own hedge about study size.
  review_notes: >-
    Historical terminology (complete, partial, marginal previa) graded how much of the
    os was covered and depended on cervical dilatation at the time of examination. It
    is not used here. The two subtypes above are the transvaginal-ultrasound
    definitions in current use.
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 520.0
  rate_low: 450.0
  rate_high: 590.0
  notes: >-
    5.2 per 1000 pregnancies. The denominator is pregnancies, not the general
    population, so this is a per-pregnancy occurrence rate and is not comparable with
    a population prevalence.
  evidence:
  - reference: PMID:23551357
    reference_title: "Prevalence of placenta praevia by world region: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The overall prevalence of placenta praevia was 5.2 per 1000 pregnancies (95% CI: 4.5-5.9)."
    explanation: Pooled worldwide per-pregnancy prevalence with its confidence interval.
- population: Asia
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1220.0
  rate_low: 950.0
  rate_high: 1520.0
  notes: >-
    12.2 per 1000 pregnancies, roughly four times the North American estimate. The
    source is explicit that it cannot tell whether this reflects true ethnic
    differences or unmeasured confounding, so it is recorded as a regional estimate
    and not as an ancestry effect.
  evidence:
  - reference: PMID:23551357
    reference_title: "Prevalence of placenta praevia by world region: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "prevalence was highest among Asian studies (12.2 per 1000 pregnancies; 95% CI: 9.5-15.2) and lower among studies from Europe (3.6 per 1000 pregnancies; 95% CI: 2.8-4.6), North America (2.9 per 1000 pregnancies; 95% CI: 2.3-3.5) and Sub-Saharan Africa (2.7 per 1000 pregnancies; 95% CI: 0.3-11.0)."
    explanation: Gives the regional breakdown; the same sentence carries the European and North American figures.
  - reference: PMID:23551357
    reference_title: "Prevalence of placenta praevia by world region: a systematic review and meta-analysis."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: "There is some evidence suggestive of regional variation in its prevalence, but it is not possible to determine from existing data whether this is due to true ethnic differences or other unknown factor(s)."
    explanation: >-
      Recorded as NO_EVIDENCE against any causal reading of the regional difference:
      the authors state their data cannot distinguish ethnicity from other factors.
- population: Pregnancies already complicated by a placenta previa (pooled cohorts)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 11100.0
  rate_low: 7650.0
  rate_high: 17350.0
  notes: >-
    The conditional rate of placenta accreta spectrum given placenta previa - 11.1%,
    IQR 7.65-17.35 - not a population figure. It is recorded here because it is the
    number that governs how a previa is managed.
  evidence:
  - reference: PMID:31722942
    reference_title: "Epidemiology of placenta previa accreta: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The incidence of PAS in women with a placenta previa was 11.10% (IQR 7.65-17.35)."
    explanation: Pooled conditional incidence of PAS among women with placenta previa.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    Placenta previa is a leading cause of bleeding in the second half of pregnancy and
    of massive obstetric haemorrhage at delivery, and it sits in the top tier of risk
    factors for postpartum haemorrhage in the pooled literature. Perinatal loss is
    mediated almost entirely through preterm delivery rather than any direct fetal
    insult, with neonatal mortality running roughly four times the background rate.
  evidence:
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Placenta previa stands as a primary cause of third-trimester hemorrhage and manifests through painless bleeding, posing life-threatening risks for both the mother and the infant"
    explanation: States the burden and the characteristic painless presentation.
  - reference: PMID:40188841
    reference_title: "Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Risk factors with a strong association with postpartum haemorrhage included anaemia, previous postpartum haemorrhage, caesarean birth, female genital mutilation, sepsis, no antenatal care, multiple pregnancy, placenta praevia, assisted reproductive technology use, macrosomia with a birthweight of more than 4500 g, and shoulder dystocia."
    explanation: >-
      Places placenta praevia in the strong-association tier (pooled OR above 2) for
      postpartum haemorrhage across 327 studies and 847 million women.
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "a study revealed a neonatal mortality rate of 10.7 per 1,000 births in previa cases, contrasting with 2.5 per 1,000 in other pregnancies (relative risk: 4.3; 95% confidence interval: 4.0, 4.8)"
    explanation: Quantifies the excess neonatal mortality relative to pregnancies without previa.
pathophysiology:
- name: Endometrial and Decidual Damage at the Lower Uterine Segment
  biological_scale: TISSUE
  description: >-
    Every well-replicated risk factor for placenta previa - prior caesarean, uterine
    curettage after induced or spontaneous abortion, intrauterine surgery,
    endometriosis, advancing maternal age - is a cause of endometrial injury. The
    proposed common step is that injury alters decidualisation and drives excessive
    vascular remodelling, so the scarred region no longer supports normal
    implantation and the blastocyst implants elsewhere, including low in the uterus.
    This is a mechanism inferred from a consistent epidemiology rather than one
    demonstrated at the implantation site in humans, and it is recorded at that
    strength.
  cell_types:
  - preferred_term: endometrial stromal cell
    term:
      id: CL:0002255
      label: stromal cell of endometrium
  - preferred_term: decidual cell
    term:
      id: CL:2000002
      label: decidual cell
  biological_processes:
  - preferred_term: decidualization
    modifier: DECREASED
    term:
      id: GO:0046697
      label: decidualization
  locations:
  - preferred_term: endometrium
    term:
      id: UBERON:0001295
      label: endometrium
  evidence:
  - reference: PMID:23127895
    reference_title: "Caesarean section in cases of placenta praevia and accreta."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These factors imply some degree of tissue damage, which can modify the decidualisation process, and produce excessive vascular remodelling."
    explanation: >-
      States the decidualisation-damage mechanism linking the shared risk factors
      (induced labour, termination, caesarean, older age) to abnormal placentation.
  - reference: PMID:34768164
    reference_title: "The risk factors associated with placenta previa: An umbrella review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "smoking (OR 1·42, 95% CI 1·30, 1·54) (RR 1·27, 95% CI: 1·18, 1·35) advanced maternal age (OR 3·16, 95% CI: 2·79, 3·57), cesarean (OR 1·60, 95% CI: 1·44, 1·76) and ART (singleton pregnancy) (RR 3·71, 95% CI: 2·67, 5·16) were graded as highly suggestive evidence (class III)."
    explanation: >-
      Umbrella review of nine meta-analyses grading the endometrial-injury risk factors
      at the highest evidence class it awards. Advanced maternal age carries the largest
      effect of the group.
  downstream:
  - target: Low Implantation of the Blastocyst
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The step from a damaged endometrium to a low implantation site is the weakest
      link in the chain. It is supported by the consistent direction of every risk
      factor and by the scar-specific version of the argument that holds for placenta
      accreta spectrum, but no human study observes the implantation event itself.
- name: Low Implantation of the Blastocyst
  biological_scale: CELLULAR
  description: >-
    The blastocyst implants in the lower uterine segment rather than the fundus. This
    node is an inferred event, not an observed one - implantation site in a human
    pregnancy is reconstructed backwards from where the placenta is later seen.
  biological_processes:
  - preferred_term: embryo implantation
    term:
      id: GO:0007566
      label: embryo implantation
  locations:
  - preferred_term: uterus
    term:
      id: UBERON:0000995
      label: uterus
  downstream:
  - target: Placental Development Overlying the Internal Cervical Os
    causal_link_type: DIRECT
- name: Placental Development Overlying the Internal Cervical Os
  biological_scale: TISSUE
  description: >-
    The placenta develops over or beside the internal os. At this point the disorder
    is a position, not yet an injury: most pregnancies diagnosed here in the second
    trimester will resolve, and the ones that do not acquire their pathology from what
    the cervix and lower segment do next.
  locations:
  - preferred_term: placenta
    term:
      id: UBERON:0001987
      label: placenta
  - preferred_term: uterine cervix
    term:
      id: UBERON:0000002
      label: uterine cervix
  evidence:
  - reference: PMID:39654466
    reference_title: Placenta Previa.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Today, placenta previa is typically identified during routine second-trimester ultrasound, with the overwhelming majority of cases resolving before term."
    explanation: >-
      Establishes that the second-trimester finding is usually transient, which is why
      the entry treats persistence rather than presence as the pathological step.
  downstream:
  - target: Failure of Trophotropic Migration Away from the Internal Os
    causal_link_type: DIRECT
  - target: Deficient Decidua Basalis Over the Uterine Scar
    causal_link_type: DIRECT
    description: >-
      This branch is taken only when the low implantation site coincides with a
      previous caesarean scar. A previa on unscarred myometrium does not take it, so
      the edge is conditional on the scar rather than obligatory.
  - target: Fetal Growth Restriction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The lower segment is less well vascularised than the fundus, which predicts
      impaired fetal growth. The measured effect is real but small, and the pooled
      estimate is highly heterogeneous - so this edge is included as a weak one rather
      than as a core feature of the disease.
    evidence:
    - reference: PMID:31301678
      reference_title: "Placenta previa and the risk of intrauterine growth restriction (IUGR): a systematic review and meta-analysis."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "pregnancies with placenta previa were associated with a mild increase in the risk of IUGR/SGA, with a pooled OR [95% confidence interval (CI)] of 1.19 (1.10-1.27)"
      explanation: >-
        1.59 million singleton pregnancies. The authors' own word for the effect is
        mild, and I2 was 94% - which the entry states rather than smoothing over.
- name: Failure of Trophotropic Migration Away from the Internal Os
  biological_scale: TISSUE
  description: >-
    Placental migration is not movement. The placenta grows preferentially toward
    the better-vascularised fundus while the tissue lying over the poorly vascularised
    cervix and lower segment atrophies, so the placental edge retreats from the os at
    roughly 5 mm per week and the great majority of second-trimester diagnoses
    resolve. Persistent placenta previa is the failure of this process - which is the
    reason the disease is defined by a third-trimester finding and why a covering
    placenta and a merely low-lying one behave so differently. The same process,
    running to completion over a velamentous cord, is the accepted explanation for
    vasa previa: the placental tissue atrophies and leaves the fetal vessels behind.
  locations:
  - preferred_term: placenta
    term:
      id: UBERON:0001987
      label: placenta
  evidence:
  - reference: PMID:37590981
    reference_title: Vasa Previa.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It has been proposed that the placenta grows preferentially toward the better-vascularized fundus of the uterus with advancing gestational age, and then the placental tissue overlying the less well-vascularized cervix and lower uterine segment undergoes atrophy, leaving behind exposed fetal vessels."
    explanation: >-
      The trophotropism mechanism, stated by the source as a proposal rather than an
      established fact - the hedge is preserved here. Quoted from the vasa previa
      literature because that is where the mechanism is articulated most explicitly.
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Research suggests a migration rate of approximately 5.4 mm per week, with over 98.4% of suspected low-lying/placenta previa cases in the second trimester resolving before delivery, typically around 26 weeks of gestation, leaving only 1.6% persisting until term"
    explanation: Quantifies both the rate of retreat and the proportion in which it succeeds.
  - reference: PMID:35841836
    reference_title: "Potential resolution of placenta previa from the 28th-to the 36th-week of pregnancy: A retrospective longitudinal cohort study."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "62.5% of the pregnant women with 28th-week placenta previa were still with previa at the 36 weeks of gestation (25.8% with marginal and 36.7% with partial/complete placenta previa)."
    explanation: >-
      REFUTE against the general reading of the 98%-resolve figure above, not against
      the migration mechanism. The resolve rate is a statement about second-trimester
      findings; in 368 women whose previa had already persisted to 28 weeks, most did
      not resolve by 36 weeks. The two figures describe different starting points, and
      quoting only the first would misdescribe the natural history of an established
      previa.
  - reference: PMID:35841836
    reference_title: "Potential resolution of placenta previa from the 28th-to the 36th-week of pregnancy: A retrospective longitudinal cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This proportion is even higher for 28th-week complete placenta previa."
    explanation: >-
      The residual migration capacity depends on how much the placenta overlaps the os,
      which is what a growth-and-atrophy mechanism predicts: the further the edge has to
      retreat, the less often it gets there.
  notes: >-
    The resolution rate quoted for this node is strongly dependent on gestational age at
    first detection, on how much the placental edge overlaps the os, and on case
    definition. Second-trimester series report over 98% resolution; a cohort already
    persisting at 28 weeks reports 62.5% still previa at 36 weeks. Both are cited above,
    as a SUPPORT and a REFUTE item, rather than reconciled into a single number.
  downstream:
  - target: Persistent Placenta Previa in the Third Trimester
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31671480
      reference_title: "Follow-up ultrasound in second-trimester low-positioned anterior and posterior placentae: prospective cohort study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In the third trimester, 48/958 (5.0%) placentae persisted as a low-positioned placenta."
      explanation: >-
        Prospective cohort measuring the failure rate of the migration process directly:
        95% of second-trimester low placentae are no longer low in the third trimester.
- name: Persistent Placenta Previa in the Third Trimester
  biological_scale: TISSUE
  description: >-
    A placenta still overlying or abutting the internal os in the third trimester. A
    prior caesarean makes persistence markedly more likely, and a posterior placenta
    persists more often than an anterior one - so the same scarring that is thought to
    cause the low implantation also makes it less likely to resolve.
  locations:
  - preferred_term: placenta
    term:
      id: UBERON:0001987
      label: placenta
  evidence:
  - reference: PMID:31671480
    reference_title: "Follow-up ultrasound in second-trimester low-positioned anterior and posterior placentae: prospective cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Women with a posterior placenta had a higher risk of a low-positioned placenta in the third trimester than did those with an anterior placenta (38/594 (6.4%) vs 10/364 (2.7%); RR, 2.4 (95% CI, 1.2-4.9)), as did women with a history of Cesarean section compared with those without such a history (14/105 (13.3%) vs 34/853 (4.0%); RR, 3.7 (95% CI, 1.9-7.2))."
    explanation: >-
      Identifies prior caesarean and posterior position as predictors of persistence,
      with effect sizes.
  downstream:
  - target: Cervical Remodelling and Lower Segment Formation at the Placental Edge
    causal_link_type: DIRECT
  - target: Poorly Contractile Placental Bed in the Lower Uterine Segment
    causal_link_type: DIRECT
  - target: Obstruction of the Birth Canal
    causal_link_type: DIRECT
- name: Cervical Remodelling and Lower Segment Formation at the Placental Edge
  biological_scale: TISSUE
  description: >-
    As term approaches, the lower uterine segment forms and the cervix softens,
    shortens and effaces. The placenta cannot accommodate that change, so the
    utero-placental interface at the placental edge is disrupted. The clinical
    signature of this being a maternal-tissue event rather than a fetal one is that the
    bleeding is bright red, painless, and of maternal origin. The evidence that
    cervical change specifically drives the bleeding is mixed and is recorded that way:
    a short cervix predicts the severe, early, emergency-delivery haemorrhage, but in
    the same cohort it did not distinguish women who bled at all from those who did not.
  locations:
  - preferred_term: uterine cervix
    term:
      id: UBERON:0000002
      label: uterine cervix
  - preferred_term: myometrium
    term:
      id: UBERON:0001296
      label: myometrium
  evidence:
  - reference: PMID:19173235
    reference_title: "Cervical length and risk of antepartum bleeding in women with complete placenta previa."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "was significantly shorter among patients who underwent emergency Cesarean section < 34 weeks due to massive hemorrhage compared with patients who underwent elective Cesarean section (29.4 +/- 5.7 mm vs. 38.8 +/- 8.5 mm; P = 0.0006)"
    explanation: >-
      A 9 mm shorter cervix in the women who bled catastrophically. INDIRECT because
      cervical length is a marker of the remodelling process rather than a measurement
      of interface disruption.
  - reference: PMID:19173235
    reference_title: "Cervical length and risk of antepartum bleeding in women with complete placenta previa."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Cervical length did not differ significantly between cases with and those without prepartum bleeding (35.3 +/- 9.3 mm vs. 38.4 +/- 8.2 mm; P = 0.18)"
    explanation: >-
      The same 59-woman cohort, and the reason this node is not asserted more strongly.
      Cervical length separated the severe cases but not bleeding as such. Kept as a
      REFUTE item against the general form of the claim rather than dropped.
  - reference: PMID:31434519
    reference_title: "Cervical length should be measured for women with placenta previa: cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Women with short cervix had significantly higher rates of preterm birth, antepartum hemorrhage, emergency cesarean sections, intraoperative estimated blood loss, massive bleeding, prevalence of placental adherence and cesarean hysterectomy"
    explanation: >-
      A larger cohort (n=328) that does find the association with antepartum haemorrhage
      itself, not only with its severe form - which is why the disagreement above is
      recorded as unresolved rather than settled against the mechanism.
  downstream:
  - target: Maternal Sinus Haemorrhage from the Placental Bed
    causal_link_type: DIRECT
- name: Maternal Sinus Haemorrhage from the Placental Bed
  biological_scale: ORGANISM
  description: >-
    Disruption of the interface opens maternal venous sinuses in the placental bed,
    and blood escapes through the cervix. Because the bleeding is maternal and the
    uterus is not contracting against a retro-placental clot, it is painless - the
    single feature that distinguishes it at the bedside from placental abruption.
  locations:
  - preferred_term: decidua basalis
    term:
      id: UBERON:0000453
      label: decidua basalis
  downstream:
  - target: Antepartum Hemorrhage
    causal_link_type: DIRECT
  - target: Hypovolemic Shock
    causal_link_type: DIRECT
  - target: Indicated Preterm Delivery
    causal_link_type: DIRECT
    description: >-
      Bleeding is the proximate trigger for early delivery, so the haemorrhage arm and
      the prematurity arm are not independent complications - one causes the other.
    evidence:
    - reference: PMID:38841031
      reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Antepartum bleeding serves as a robust predictor of preterm delivery in pregnancies complicated by placenta previa"
      explanation: Links the haemorrhage node to the preterm-delivery node directly.
- name: Deficient Decidua Basalis Over the Uterine Scar
  biological_scale: TISSUE
  description: >-
    Where the low-implanting placenta lands on a caesarean scar, the scar has not
    re-epithelialised and the decidua basalis is absent or deficient. The decidua is
    the brake on extravillous trophoblast migration, so its absence permits otherwise
    normal placentation to proceed into the myometrium. This is the mechanism shared
    with the Placenta Accreta Spectrum entry, reached here from the previa side: it is
    why previa and prior caesarean multiply rather than merely add.
  cell_types:
  - preferred_term: decidual cell
    term:
      id: CL:2000002
      label: decidual cell
  locations:
  - preferred_term: decidua basalis
    term:
      id: UBERON:0000453
      label: decidua basalis
  evidence:
  - reference: PMID:24338130
    reference_title: "Risk factors for placenta accreta: a large prospective cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "as were women with previa (adjusted odds ratio [OR], 34.9; 95% confidence interval [CI], 22.4-54.3)"
    explanation: >-
      73,257 caesarean deliveries. A 35-fold adjusted odds ratio is the largest single
      risk factor for accreta in the cohort, which is why previa is treated here as a
      cause of PAS rather than a co-finding.
  - reference: PMID:24338130
    reference_title: "Risk factors for placenta accreta: a large prospective cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients with previa and two or three prior cesarean deliveries had an adjusted OR for accreta of 4.9 (95% CI, 1.7-14.3) or 7.7 (95% CI, 2.4-24.9), respectively"
    explanation: >-
      Within the previa group alone, risk scales with the number of scars - the
      dose-response that the deficient-decidua mechanism predicts.
  - reference: PMID:28268196
    reference_title: "Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The incidence of placenta previa accreta was 4.1% in women with 1 prior cesarean and 13.3% in women with ≥2 previous cesarean deliveries."
    explanation: The same dose-response in a 3,889-pregnancy meta-analysis, as absolute incidences.
  downstream:
  - target: Unimpeded Extravillous Trophoblast Invasion of the Myometrium
    causal_link_type: DIRECT
- name: Unimpeded Extravillous Trophoblast Invasion of the Myometrium
  biological_scale: CELLULAR
  description: >-
    Extravillous trophoblast migrates into the myometrium because the decidual barrier
    that normally limits it is not there. The sonographic correlate at the previa site
    is lower-segment hypervascularity and large, swirling placental lacunae, detectable
    as early as the first trimester.
  cell_types:
  - preferred_term: extravillous trophoblast
    term:
      id: CL:0008036
      label: extravillous trophoblast
  biological_processes:
  - preferred_term: trophoblast cell migration
    modifier: INCREASED
    term:
      id: GO:0061450
      label: trophoblast cell migration
  - preferred_term: blood vessel remodeling
    modifier: INCREASED
    term:
      id: GO:0001974
      label: blood vessel remodeling
  locations:
  - preferred_term: myometrium
    term:
      id: UBERON:0001296
      label: myometrium
  evidence:
  - reference: PMID:34837427
    reference_title: "First-trimester ultrasound diagnostic features of placenta accreta spectrum in low-implantation pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lower uterine segment (uterovesical, subplacental and/or intraplacental) hypervascularity was present in 14/14 (100%) cases and only 1/12 (8.3%) controls (P < 0.001)."
    explanation: >-
      Case-control study in which both arms are low-implantation pregnancies, so the
      comparison isolates the invasion signal rather than the low position.
  - reference: PMID:34837427
    reference_title: "First-trimester ultrasound diagnostic features of placenta accreta spectrum in low-implantation pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Placental lacunae were present in 18/21 (85.7%) cases and 7/46 (15.2%) controls (odds ratio (OR), 33.4; 95% CI, 7.7-144.4; P < 0.001)."
    explanation: The lacunae marker in the same first-trimester low-implantation comparison.
  downstream:
  - target: Failure of Placental Separation at Delivery
    causal_link_type: DIRECT
- name: Failure of Placental Separation at Delivery
  biological_scale: TISSUE
  description: >-
    Villi anchored in the myometrium cannot shear off at the decidual plane, so the
    third stage does not complete. Attempting to remove the placenta tears the
    myometrium and opens the invaded vasculature - which is why the standard of care is
    to leave it alone and proceed to hysterectomy.
  locations:
  - preferred_term: myometrium
    term:
      id: UBERON:0001296
      label: myometrium
  evidence:
  - reference: PMID:16582134
    reference_title: "Placenta previa, placenta accreta, and vasa previa."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Women known to have placenta accreta should be delivered by cesarean, and no attempt should be made to separate the placenta at the time of delivery."
    explanation: >-
      The management rule follows from the mechanism: separation is not achievable, so
      attempting it converts a controlled delivery into a haemorrhage.
  downstream:
  - target: Post-partum Hemorrhage
    causal_link_type: DIRECT
- name: Poorly Contractile Placental Bed in the Lower Uterine Segment
  biological_scale: TISSUE
  description: >-
    After any delivery, haemostasis at the placental bed is mechanical: myometrial
    contraction occludes the spiral arteries. The lower uterine segment is a poorly
    contractile part of the uterus, so a placental bed sited there does not get that
    closure, and the newly formed vessels of the abnormally remodelled bed keep
    bleeding. This is why postpartum haemorrhage in previa happens even when the
    placenta separates normally and there is no accreta - it is a separate mechanism
    from the one above, converging on the same phenotype.
  locations:
  - preferred_term: myometrium
    term:
      id: UBERON:0001296
      label: myometrium
  evidence:
  - reference: PMID:23127895
    reference_title: "Caesarean section in cases of placenta praevia and accreta."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Placenta praevia and accreta are mainly located in the lower segment, a place that predisposes to persistent uterine bleeding because of the development of new vessels and because it is a poorly contractile area of the uterus."
    explanation: >-
      States both components of this node - neovascularisation and the contractile
      deficit of the lower segment - as the reason bleeding persists after delivery.
  downstream:
  - target: Post-partum Hemorrhage
    causal_link_type: DIRECT
- name: Obstruction of the Birth Canal
  biological_scale: ORGANISM
  description: >-
    The placenta lies between the fetus and the cervix. Labour would deliver the
    placenta first, detaching the fetal circulation before the fetus is born, so
    vaginal delivery is not available and abdominal delivery is obligatory rather than
    merely preferred. A low-lying placenta more than 2 cm from the os is the exception.
  locations:
  - preferred_term: uterine cervix
    term:
      id: UBERON:0000002
      label: uterine cervix
  evidence:
  - reference: PMID:16582134
    reference_title: "Placenta previa, placenta accreta, and vasa previa."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnostic modality of choice for placenta previa is transvaginal ultrasonography, and women with a complete placenta previa should be delivered by cesarean."
    explanation: States the obligate abdominal route for a covering placenta.
  downstream:
  - target: Indicated Preterm Delivery
    causal_link_type: DIRECT
- name: Indicated Preterm Delivery
  biological_scale: ORGANISM
  description: >-
    Delivery is scheduled before term to pre-empt catastrophic haemorrhage, or happens
    as an emergency when haemorrhage occurs. Either way prematurity in placenta previa
    is substantially iatrogenic and deliberate - a chosen trade of neonatal risk against
    maternal risk - which is a different thing from spontaneous preterm labour and is
    the reason antenatal corticosteroids are a mainstay.
  evidence:
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Preterm birth emerges as a prevalent complication linked to placenta previa, with approximately 5% of all preterm deliveries attributed to this condition"
    explanation: >-
      Gives the population-level contribution of previa to preterm birth, which is large
      relative to the condition's 0.5% prevalence.
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "for uncomplicated complete placenta previa, scheduling delivery between 36 and 37 weeks is advisable"
    explanation: >-
      Documents that the timing is planned rather than spontaneous, supporting the
      iatrogenic framing of this node.
  downstream:
  - target: Premature Birth
    causal_link_type: DIRECT
  - target: Neonatal Death
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Mediated by the recognised complications of prematurity - respiratory distress
      syndrome, low birth weight and birth asphyxia - rather than by the placental
      position acting on the fetus directly.
phenotypes:
- category: Clinical
  name: Antepartum Hemorrhage
  description: >-
    Painless, bright-red vaginal bleeding in the second half of pregnancy, classically
    unprovoked and recurrent. Roughly half of women with a complete previa persisting
    into the third trimester bleed before delivery. The painlessness is diagnostic
    information, not a detail: it is what separates previa from abruption at
    presentation.
  phenotype_term:
    preferred_term: Antepartum hemorrhage
    term:
      id: HP:0025328
      label: Antepartum hemorrhage
    temporality: RECURRENT
  frequency: FREQUENT
  evidence:
  - reference: PMID:19173235
    reference_title: "Cervical length and risk of antepartum bleeding in women with complete placenta previa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Twenty-nine (49.1%) of the women presented prepartum bleeding and 12 (20.3%) required an emergency Cesarean section prior to 34 completed weeks due to massive hemorrhage."
    explanation: >-
      Gives the frequency in a cohort restricted to complete previa persisting into the
      third trimester, which is the population this frequency band is about.
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Placenta previa stands as a primary cause of third-trimester hemorrhage and manifests through painless bleeding, posing life-threatening risks for both the mother and the infant"
    explanation: Establishes the painless character of the bleeding.
- category: Clinical
  name: Post-partum Hemorrhage
  description: >-
    Excessive blood loss after delivery, reached by two independent routes in this
    disease - a placental bed in a poorly contractile segment, and, when accreta is
    superimposed, a placenta that will not separate at all.
  phenotype_term:
    preferred_term: Post-partum hemorrhage
    term:
      id: HP:0011891
      label: Post-partum hemorrhage
  evidence:
  - reference: PMID:40188841
    reference_title: "Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Risk factors with a strong association with postpartum haemorrhage included anaemia, previous postpartum haemorrhage, caesarean birth, female genital mutilation, sepsis, no antenatal care, multiple pregnancy, placenta praevia, assisted reproductive technology use, macrosomia with a birthweight of more than 4500 g, and shoulder dystocia."
    explanation: >-
      Places placenta praevia in the highest association tier the review defines
      (pooled OR greater than 2).
- category: Clinical
  name: Hypovolemic Shock
  description: >-
    Massive antepartum or peripartum blood loss can produce haemorrhagic shock and is
    the route by which placenta previa kills. About one in five women with a persistent
    complete previa in one cohort required emergency delivery before 34 weeks for
    massive haemorrhage.
  phenotype_term:
    preferred_term: Hypovolemic shock
    term:
      id: HP:0031274
      label: Hypovolemic shock
    temporality: ACUTE
  evidence:
  - reference: PMID:19173235
    reference_title: "Cervical length and risk of antepartum bleeding in women with complete placenta previa."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Twenty-nine (49.1%) of the women presented prepartum bleeding and 12 (20.3%) required an emergency Cesarean section prior to 34 completed weeks due to massive hemorrhage."
    explanation: >-
      INDIRECT because the cohort reports emergency delivery for massive haemorrhage
      rather than measured haemodynamic shock, so the phenotype is inferred from the
      intervention it prompted.
- category: Clinical
  name: Premature Birth
  description: >-
    Delivery before 37 weeks, largely by obstetric indication rather than spontaneous
    labour. Placenta previa accounts for about 5% of all preterm deliveries.
  phenotype_term:
    preferred_term: Premature birth
    term:
      id: HP:0001622
      label: Premature birth
  frequency: FREQUENT
  evidence:
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Preterm birth emerges as a prevalent complication linked to placenta previa, with approximately 5% of all preterm deliveries attributed to this condition"
    explanation: Quantifies previa's share of the population burden of preterm birth.
- category: Clinical
  name: Fetal Growth Restriction
  description: >-
    Birth weight below the 10th percentile, mildly more common than in pregnancies with
    a normally sited placenta. The effect is small (OR 1.19) and heterogeneous, and the
    entry deliberately does not present it as a characteristic feature.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:31301678
    reference_title: "Placenta previa and the risk of intrauterine growth restriction (IUGR): a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The incidence of growth abnormalities was 8.7/100 births in cases of placenta previa vs. 5.8/100 births among controls."
    explanation: >-
      Absolute incidences behind the pooled odds ratio, which is what the OCCASIONAL
      band is set from.
- category: Clinical
  name: Neonatal Death
  description: >-
    Neonatal mortality is about four times the background rate, mediated by prematurity,
    low birth weight, asphyxia and respiratory distress rather than by a direct effect
    of the placental position on the fetus.
  phenotype_term:
    preferred_term: Neonatal death
  frequency: VERY_RARE
  evidence:
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "a study revealed a neonatal mortality rate of 10.7 per 1,000 births in previa cases, contrasting with 2.5 per 1,000 in other pregnancies (relative risk: 4.3; 95% confidence interval: 4.0, 4.8)"
    explanation: >-
      10.7 per 1000 is about 1%, which sets the VERY_RARE frequency band even though the
      relative risk is fourfold.
  notes: >-
    Deliberately left unbound. HPO has a term - HP:0003811 Neonatal death - but it sits
    under Mortality/Aging rather than under HP:0000118 phenotypic abnormality, so it is
    outside the PhenotypeTerm dynamic-enum root and binding it fails term validation.
    This is the same enum-root gap that issue #7837 records for HP:0003826 Stillbirth,
    HP:0009800 Maternal diabetes and HP:0100602 Preeclampsia; Intrahepatic Cholestasis
    of Pregnancy leaves its stillbirth phenotype unbound for the same reason. Recorded
    here as a fourth instance rather than worked around.
diagnosis:
- name: Transvaginal Ultrasonography
  description: >-
    The diagnostic standard. Transvaginal scanning measures the placental edge to
    internal-os distance directly. Diagnosis is made in the third trimester, because a
    second-trimester finding usually resolves.
  diagnosis_term:
    preferred_term: transvaginal ultrasound
    term:
      id: NCIT:C17644
      label: Transvaginal Ultrasound
  evidence:
  - reference: PMID:16582134
    reference_title: "Placenta previa, placenta accreta, and vasa previa."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnostic modality of choice for placenta previa is transvaginal ultrasonography, and women with a complete placenta previa should be delivered by cesarean."
    explanation: Names transvaginal ultrasonography as the modality of choice.
  - reference: PMID:31671480
    reference_title: "Follow-up ultrasound in second-trimester low-positioned anterior and posterior placentae: prospective cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Low-positioned placenta included placenta previa, defined as a placenta covering the internal os of the cervix, and a low-lying placenta, defined as a placenta lying near to (within 20 mm) but not overlying the internal os."
    explanation: Gives the measured criteria the scan applies.
- name: Assessment for Placenta Accreta Spectrum
  description: >-
    A diagnosis of previa is also an indication to look for PAS, because roughly one in
    nine previas has it and the management differs completely. Lower-segment
    hypervascularity, placental lacunae and loss of the clear zone are assessable from
    the first trimester in a low-implantation pregnancy.
  diagnosis_term:
    preferred_term: fetal ultrasound imaging
    term:
      id: NCIT:C222238
      label: Fetal Ultrasound Imaging
  evidence:
  - reference: PMID:39654466
    reference_title: Placenta Previa.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "When placenta previa is diagnosed, it is essential to assess for associated conditions like placenta accreta and vasa previa."
    explanation: States the obligation to screen for PAS and vasa previa once previa is found.
  - reference: PMID:34837427
    reference_title: "First-trimester ultrasound diagnostic features of placenta accreta spectrum in low-implantation pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In women at risk of PAS, ultrasound markers of PAS can and should be assessed as early as in the first trimester."
    explanation: Supports first-trimester rather than third-trimester assessment in this population.
environmental:
- name: Maternal Cigarette Smoking
  description: >-
    Smoking in pregnancy raises previa risk by about 40%. The usual proposed mechanism
    is that carbon-monoxide-mediated relative hypoxaemia drives compensatory placental
    enlargement, so the placenta spreads far enough to reach the lower segment - but the
    cited evidence is epidemiological and identifies no mediating step, so the link is
    recorded as an association with an unestablished mechanism.
  exposure_term:
    preferred_term: exposure to cigarette smoking via maternal
    term:
      id: ECTO:0300003
      label: exposure to cigarette smoking via maternal
  influences_mechanisms:
  - target: Placental Development Overlying the Internal Cervical Os
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A consistent, modest association with no demonstrated intermediate. Included
      because smoking is the main modifiable risk factor in the set, not because the
      mechanism is established.
    evidence:
    - reference: PMID:27936997
      reference_title: "Smoking and placenta previa: a meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "compared to nonsmoker women, the estimated OR and RR of placenta previa was 1.42 (95% CI: 1.30, 1.54) and 1.27 (95% CI: 1.18, 1.35), respectively"
      explanation: >-
        Meta-analysis over 9,094,443 participants giving both the odds-ratio and
        relative-risk forms of the association.
  evidence:
  - reference: PMID:34768164
    reference_title: "The risk factors associated with placenta previa: An umbrella review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "smoking (OR 1·42, 95% CI 1·30, 1·54) (RR 1·27, 95% CI: 1·18, 1·35) advanced maternal age (OR 3·16, 95% CI: 2·79, 3·57), cesarean (OR 1·60, 95% CI: 1·44, 1·76) and ART (singleton pregnancy) (RR 3·71, 95% CI: 2·67, 5·16) were graded as highly suggestive evidence (class III)."
    explanation: >-
      The umbrella review grades smoking at its highest awarded evidence class, alongside
      the other established risk factors.
- name: Endometriosis
  description: >-
    Endometriosis nearly triples the risk of placenta previa, and the effect is strongly
    dose-dependent on disease severity - roughly sevenfold for revised-ASRM stage III-IV
    disease and fourteenfold for deep endometriosis. Critically, the association holds
    regardless of whether conception was assisted, which separates it from the
    ART-related risk and points at the endometrium itself rather than at the procedures.
  exposure_term:
    preferred_term: pre-pregnancy endometriosis
  influences_mechanisms:
  - target: Endometrial and Decidual Damage at the Lower Uterine Segment
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The severity gradient is the informative part: a risk factor whose effect scales
      with how much endometrial and pelvic disease is present is consistent with the
      decidualisation-damage node, though the study measures outcome rather than
      decidualisation.
    evidence:
    - reference: PMID:39049473
      reference_title: "Untangling the independent effect of endometriosis, adenomyosis, and ART-related factors on maternal, placental, fetal, and neonatal adverse outcomes: results from a systematic review and meta-analysis."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "The association was observed regardless of the method of conception and was particularly strong in the most severe forms of endometriosis (i.e. rASRM stage III-IV endometriosis and deep endometriosis (DE)) (OR 6.61; 95% CI: 2.08, 20.98; I2 = 66% and OR 14.54; 95% CI: 3.67, 57.67; I2 = 54%, respectively)"
      explanation: >-
        Establishes both the independence from conception method and the severity
        gradient. INDIRECT because the inference from worse endometrial disease to the
        decidualisation node is a step the study does not take.
  evidence:
  - reference: PMID:39049473
    reference_title: "Untangling the independent effect of endometriosis, adenomyosis, and ART-related factors on maternal, placental, fetal, and neonatal adverse outcomes: results from a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We showed a higher risk of placenta previa in women with endometriosis compared to controls (34 studies, OR 2.84; 95% CI: 2.47, 3.26; I2 = 83%, moderate quality)"
    explanation: The headline pooled association across 34 studies, graded moderate quality by GRADE.
- name: Assisted Reproductive Technology
  description: >-
    ART in a singleton pregnancy carries a nearly fourfold relative risk of placenta
    previa - the largest effect among the established risk factors. Whether this is the
    technology, the underlying subfertility, or the endometrial pathology that caused
    the subfertility is unresolved; the endometriosis data above show that at least one
    component is independent of the method of conception.
  exposure_term:
    preferred_term: conception by assisted reproductive technology
  influences_mechanisms:
  - target: Low Implantation of the Blastocyst
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Embryo transfer places the blastocyst mechanically rather than letting it
      implant where it arrives, which is an obvious candidate mechanism for an altered
      implantation site - but it is a hypothesis, and the cited evidence does not test it.
    evidence:
    - reference: PMID:34768164
      reference_title: "The risk factors associated with placenta previa: An umbrella review."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "smoking (OR 1·42, 95% CI 1·30, 1·54) (RR 1·27, 95% CI: 1·18, 1·35) advanced maternal age (OR 3·16, 95% CI: 2·79, 3·57), cesarean (OR 1·60, 95% CI: 1·44, 1·76) and ART (singleton pregnancy) (RR 3·71, 95% CI: 2·67, 5·16) were graded as highly suggestive evidence (class III)."
      explanation: >-
        Gives the ART effect size (RR 3.71) at the review's highest evidence class.
        INDIRECT because nothing in the quote bears on the implantation-site step.
  evidence:
  - reference: PMID:34768164
    reference_title: "The risk factors associated with placenta previa: An umbrella review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study provides suggestive evidence about prior spontaneous abortion, prior induced abortion, male fetus, smoking, advanced maternal age, cesarean section, and assisted reproductive techniques (singleton pregnancy) as risk factors associated with placenta previa."
    explanation: >-
      The umbrella review's own summary statement, listing assisted reproductive
      techniques among the risk factors it grades at class III.
  - reference: PMID:26244528
    reference_title: "Abnormal Placentation: Placenta Previa, Vasa Previa, and Placenta Accreta."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the rates of previa and accreta are increasing, probably as a result of increasing rates of cesarean delivery, maternal age, and assisted reproductive technology"
    explanation: >-
      Attributes the secular rise in previa incidence partly to ART uptake, which is the
      population-level reason this exposure matters rather than only the per-pregnancy
      relative risk.
treatments:
- name: Planned Cesarean Delivery
  description: >-
    The definitive management, and the intervention that turned placenta previa from a
    major cause of maternal death into a manageable condition. A covering placenta
    mandates it; a low-lying placenta more than 2 cm from the os may allow a trial of
    vaginal delivery. Scheduling is a deliberate trade: 36-37 weeks for an uncomplicated
    complete previa balances the bleeding risk of waiting against the neonatal risk of
    delivering early. Delivery should be at an institution able to transfuse.
  treatment_term:
    preferred_term: cesarean delivery
    term:
      id: NCIT:C46088
      label: Cesarean Section
  therapeutic_modality: SURGERY
  target_mechanisms:
  - target: Obstruction of the Birth Canal
    description: >-
      Bypasses the obstruction rather than correcting it - the placental position is
      unchanged, the fetus simply does not have to pass it.
  - target: Cervical Remodelling and Lower Segment Formation at the Placental Edge
    description: >-
      Pre-empting labour prevents the cervical change that disrupts the interface, which
      is why scheduled delivery is the whole strategy rather than a fallback.
  evidence:
  - reference: PMID:39654466
    reference_title: Placenta Previa.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A planned cesarean delivery is recommended in cases that persist into the late third trimester."
    explanation: States the recommendation for the persistent case, which is the treated population.
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "for uncomplicated complete placenta previa, scheduling delivery between 36 and 37 weeks is advisable"
    explanation: Gives the timing and the reasoning behind it.
  - reference: PMID:16582134
    reference_title: "Placenta previa, placenta accreta, and vasa previa."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Delivery should take place at an institution with adequate blood banking facilities."
    explanation: Records the setting requirement, which follows from the haemorrhage risk.
- name: Antenatal Corticosteroid Therapy
  description: >-
    Given because delivery in placenta previa is expected to be preterm. It targets the
    consequence of the obstetric decision rather than the placental disorder - the
    clearest example in this entry of a treatment aimed at an iatrogenic arm of the
    pathograph.
  treatment_term:
    preferred_term: antenatal corticosteroid administration
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
    therapeutic_agent:
    - preferred_term: betamethasone
      term:
        id: CHEBI:3077
        label: betamethasone
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Indicated Preterm Delivery
    description: >-
      Mitigates the neonatal consequences of early delivery; it does not reduce the
      likelihood of early delivery.
  evidence:
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ACS has since demonstrated a capacity to decrease the risk of late miscarriages, infant deaths, RDS, intraventricular hemorrhage, necrotizing enterocolitis, and systemic infections within the first two days of life"
    explanation: >-
      Summarises the neonatal benefit of antenatal corticosteroids. Note this is the
      general preterm-birth evidence base, not a previa-specific trial.
  notes: >-
    The efficacy evidence quoted is for antenatal corticosteroids in preterm birth
    generally, not for placenta previa specifically. No previa-restricted randomised
    trial is cited here, and the entry does not imply one exists.
- name: Blood Transfusion and Haemorrhage Support
  description: >-
    Supportive rather than mechanistic: replaces what is lost while the bleeding source
    is addressed surgically. Its availability is a precondition for delivering a previa
    safely rather than an optional adjunct.
  treatment_term:
    preferred_term: blood transfusion
    term:
      id: NCIT:C15192
      label: Blood Transfusion
  target_mechanisms:
  - target: Hypovolemic Shock
    description: Restores circulating volume and oxygen-carrying capacity.
  evidence:
  - reference: PMID:16582134
    reference_title: "Placenta previa, placenta accreta, and vasa previa."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Delivery should take place at an institution with adequate blood banking facilities."
    explanation: Establishes transfusion capacity as a requirement of the delivery plan.
- name: Uterotonic Therapy
  description: >-
    First pharmacological step once the placenta is delivered and the bed is bleeding.
    Oxytocin and the prostaglandin analogue misoprostol drive myometrial contraction to
    close the spiral arteries mechanically. The important qualification in previa is that
    the bleeding bed is the lower uterine segment, which is thin and comparatively
    fibrous, so it contracts poorly by comparison with the fundus; uterotonics therefore
    work less well here than in atonic post-partum haemorrhage from a normally sited
    placenta, and are the first rung of an escalation ladder rather than a definitive
    answer. This entry records the intervention and its mechanism; no efficacy figure is
    recorded because the cited trial registration carries no results.
  treatment_term:
    preferred_term: uterotonic pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: oxytocin
      term:
        id: CHEBI:7872
        label: oxytocin
    - preferred_term: misoprostol
      term:
        id: CHEBI:63610
        label: misoprostol
  target_mechanisms:
  - target: Poorly Contractile Placental Bed in the Lower Uterine Segment
    treatment_effect: INHIBITS
    description: >-
      Stimulates myometrial contraction to compress the open sinuses. Effect is limited
      by the very property this node names - the lower segment contracts poorly - which
      is why the ladder continues past this step.
  - target: Post-partum Hemorrhage
    treatment_effect: INHIBITS
    description: Reduces blood loss by achieving mechanical haemostasis at the placental bed.
  evidence:
  - reference: clinicaltrials:NCT05340205
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "To compare the efficacy and safety profile of intravenous tranexamic acid versus intrauterine misoprostol in reducing the blood loss during and after cesarean delivery in pregnant women diagnosed with placenta previa"
    explanation: >-
      Registration record establishing that intrauterine misoprostol is used to reduce
      blood loss at caesarean delivery specifically in placenta previa. Graded OTHER
      because a trial registration is a design document, not a reported study result;
      the registry carries no outcome values, so no efficacy claim is made here.
  notes: >-
    therapeutic_modality is deliberately left unset. The slot is single-valued and this
    treatment bundles a nonapeptide (oxytocin, PEPTIDE) with a small-molecule
    prostaglandin analogue (misoprostol, SMALL_MOLECULE); either value would be wrong
    for half the entry.
- name: Tranexamic Acid
  description: >-
    Antifibrinolytic given to limit clot breakdown at the bleeding placental bed. It acts
    on the haemostatic arm rather than the contractile one, which is what makes it
    complementary to uterotonics in a bed that contracts poorly - the mechanism does not
    depend on the myometrium. Used peri-operatively at caesarean delivery in previa.
  treatment_term:
    preferred_term: antifibrinolytic pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tranexamic acid
      term:
        id: CHEBI:48669
        label: tranexamic acid
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Maternal Sinus Haemorrhage from the Placental Bed
    treatment_effect: INHIBITS
    description: >-
      Inhibits fibrinolysis so that clot formed over the open maternal sinuses is not
      broken down, acting independently of myometrial contraction.
  - target: Post-partum Hemorrhage
    treatment_effect: INHIBITS
    description: Reduces total blood loss during and after caesarean delivery.
  evidence:
  - reference: clinicaltrials:NCT05340205
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "To compare the efficacy and safety profile of intravenous tranexamic acid versus intrauterine misoprostol in reducing the blood loss during and after cesarean delivery in pregnant women diagnosed with placenta previa"
    explanation: >-
      Registration record establishing intravenous tranexamic acid as a blood-loss
      reducing intervention at caesarean delivery in placenta previa. Graded OTHER as a
      design document; the registry reports no outcome values, so efficacy is not claimed.
- name: Intrauterine Balloon Tamponade
  description: >-
    Mechanical second-line measure: a balloon catheter inflated in the uterine cavity
    applies direct pressure to the bleeding lower-segment bed. Because it substitutes
    externally applied pressure for myometrial contraction, it addresses the specific
    failure mode of previa haemorrhage rather than depending on it, and it is explicitly
    a uterus-preserving alternative to hysterectomy.
  treatment_term:
    preferred_term: intrauterine balloon tamponade
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  therapeutic_modality: DEVICE
  target_mechanisms:
  - target: Poorly Contractile Placental Bed in the Lower Uterine Segment
    treatment_effect: BYPASSES
    description: >-
      Supplies mechanical compression from within the cavity, working around the poor
      contractility of the lower segment instead of trying to correct it.
  - target: Maternal Sinus Haemorrhage from the Placental Bed
    treatment_effect: INHIBITS
    description: Direct pressure closes the open maternal sinuses.
  evidence:
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Conservative management involves prophylactic double bilateral ligation of uterine arteries before placental removal, followed by tamponade using a saline-filled balloon catheter"
    explanation: >-
      Places balloon tamponade in the conservative-management arm for placenta previa.
      Graded OTHER with quote_role REVIEW_SYNTHESIS because the sentence is this review's
      summary of reference [38] rather than its own observation.
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "This strategy aims to circumvent hysterectomy and safeguard the patient's future fertility"
    explanation: Sources the stated purpose of the conservative arm - uterine preservation.
  - reference: clinicaltrials:NCT05133167
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage."
    explanation: >-
      Registration record for a completed previa-specific randomized trial, establishing
      the intra-operative use of Foley-balloon tamponade. Cited for design, not efficacy -
      the registry carries no outcome values.
- name: Uterine Compression Sutures
  description: >-
    Surgical apposition of the uterine walls (B-Lynch or parallel vertical compression
    sutures) to compress the bleeding bed, used intra-operatively at caesarean when
    pharmacological measures have not controlled the loss. Like tamponade, it is a
    uterus-preserving step taken before hysterectomy is accepted.
  treatment_term:
    preferred_term: uterine compression suture placement
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  therapeutic_modality: SURGERY
  target_mechanisms:
  - target: Poorly Contractile Placental Bed in the Lower Uterine Segment
    treatment_effect: BYPASSES
    description: >-
      Externally applied surgical compression substitutes for the contraction the lower
      segment cannot generate.
  - target: Post-partum Hemorrhage
    treatment_effect: INHIBITS
    description: Controls ongoing intra-operative blood loss short of hysterectomy.
  evidence:
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Other hemorrhage control measures may include B-Lynch or parallel vertical compression sutures, uterine artery ligation (O'Leary stitch), and aortic balloon occlusion before C-HYST"
    explanation: >-
      Names compression sutures among the haemorrhage-control measures used before
      caesarean hysterectomy is accepted. Graded OTHER with quote_role REVIEW_SYNTHESIS -
      the sentence is the review's synthesis of reference [40].
  - reference: clinicaltrials:NCT05133167
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage."
    explanation: >-
      Registration record establishing intra-operative B-Lynch suture use in placenta
      previa. Cited for design only; no outcome values are registered.
- name: Pelvic Arterial Embolization
  description: >-
    Interventional-radiology control of the uterine and pelvic arterial supply, either as
    pre-delivery catheter placement in anticipated accreta spectrum or as rescue when
    bleeding continues. It acts on arterial inflow rather than on the myometrium, and is
    the last uterus-preserving rung before hysterectomy.
  treatment_term:
    preferred_term: pelvic arterial embolization
    term:
      id: NCIT:C15917
      label: Arterial Embolization
  target_mechanisms:
  - target: Maternal Sinus Haemorrhage from the Placental Bed
    treatment_effect: INHIBITS
    description: >-
      Occludes the arterial supply feeding the placental bed, reducing inflow to the open
      maternal sinuses.
  evidence:
  - reference: PMID:38841031
    reference_title: "Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "interventions such as balloon catheters for angiographic embolization of pelvic vessels and aortic balloon occlusion preceding cesarean hysterectomy (C-HYST) deployed to mitigate hemorrhage"
    explanation: >-
      Establishes angiographic embolization of pelvic vessels as a blood-loss control
      measure in this setting. Graded OTHER with quote_role REVIEW_SYNTHESIS as the
      review's restatement of reference [19].
  notes: >-
    therapeutic_modality is left unset. The procedure is catheter-delivered interventional
    radiology, which is neither SURGERY nor DEVICE in the sense the enum's other uses
    carry; rather than stretch one, the slot is omitted.
- name: Peripartum Hysterectomy
  description: >-
    The endpoint when the placenta cannot be separated, which in practice means when
    accreta spectrum is superimposed on the previa. It is a definitive haemostatic
    operation and an irreversible one; the great majority of significant accreta cases
    need it.
  treatment_term:
    preferred_term: peripartum hysterectomy
    term:
      id: NCIT:C15256
      label: Hysterectomy
  therapeutic_modality: SURGERY
  target_mechanisms:
  - target: Failure of Placental Separation at Delivery
    description: >-
      Removes the uterus with the placenta in situ, so the un-separable interface is
      never disturbed.
  - target: Poorly Contractile Placental Bed in the Lower Uterine Segment
    description: >-
      Also removes the bleeding bed itself, which is why it works when uterotonics -
      which depend on a contractile myometrium - do not.
  evidence:
  - reference: PMID:16582134
    reference_title: "Placenta previa, placenta accreta, and vasa previa."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The majority of women with significant degrees of placenta accreta will require a hysterectomy."
    explanation: States the frequency with which the definitive operation is needed.
  - reference: PMID:16582134
    reference_title: "Placenta previa, placenta accreta, and vasa previa."
    supports: NO_EVIDENCE
    evidence_source: OTHER
    snippet: "Although successful conservative management has been described, there are currently insufficient data to recommend this approach to management routinely."
    explanation: >-
      Recorded as NO_EVIDENCE for the uterus-preserving alternative: the source reports
      it exists and explicitly declines to judge it, which is not support either way.
clinical_trials:
- name: NCT05133167
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Randomized open-label trial (n=60, Pakistan) comparing Foley-balloon tamponade with
    B-Lynch compression suture for prevention of post-partum haemorrhage in placenta
    previa, with 24-hour blood loss as the primary endpoint. Recorded for the two
    uterus-preserving interventions it tests head to head; the registry carries no
    result values, so no efficacy comparison is drawn.
  target_phenotypes:
  - preferred_term: Post-partum hemorrhage
    term:
      id: HP:0011891
      label: Post-partum hemorrhage
  evidence:
  - reference: clinicaltrials:NCT05133167
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage."
    explanation: >-
      Registration record describing both arms. Graded OTHER because a registration is a
      design document rather than a reported result.
- name: NCT05340205
  phase: PHASE_IV
  status: COMPLETED
  description: >-
    Completed phase 4 randomized open-label trial (n=81, Cairo University) comparing
    intravenous tranexamic acid with intrauterine misoprostol for reduction of blood loss
    during and after caesarean delivery in placenta previa. Recorded for the
    pharmacological arms of the escalation ladder; the registry holds no outcome values,
    so it is cited for design only.
  target_phenotypes:
  - preferred_term: Post-partum hemorrhage
    term:
      id: HP:0011891
      label: Post-partum hemorrhage
  evidence:
  - reference: clinicaltrials:NCT05340205
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "To compare the efficacy and safety profile of intravenous tranexamic acid versus intrauterine misoprostol in reducing the blood loss during and after cesarean delivery in pregnant women diagnosed with placenta previa"
    explanation: >-
      Registration record stating both pharmacological arms and the population. Graded
      OTHER as a design document with no registered results.
discussions:
- discussion_id: previa_cervical_remodelling_vs_severity_marker
  kind: CONTROVERSY
  prompt: >-
    Does cervical remodelling cause the antepartum bleeding in placenta previa, or does
    it only mark the subset that bleeds catastrophically?
  attaches_to:
  - pathophysiology#Cervical Remodelling and Lower Segment Formation at the Placental Edge
  rationale: >-
    The two cohorts cited on that node disagree, and they disagree in a way that matters
    for the mechanism rather than only for prediction. Ghi and colleagues (n=59,
    complete previa only) found cervical length significantly shorter in women needing
    emergency delivery for massive haemorrhage but not different between women who bled
    and women who did not - which would make cervical shortening a severity marker,
    not the cause of bleeding as such. Altraigey and colleagues (n=328, previa and/or
    accreta) found short cervix associated with antepartum haemorrhage itself. The
    cohorts differ in size, in case mix, and in whether accreta was included, so the
    discrepancy has an obvious candidate explanation and no resolving study is cited
    here. The textbook account - lower-segment formation shears an inelastic placenta
    off the decidua - is mechanically plausible and is what every review states, but no
    reference in this entry demonstrates the shearing event directly.
- discussion_id: previa_why_low_implantation
  kind: KNOWLEDGE_GAP
  prompt: >-
    Why does the placenta implant low in the first place, and is a damaged endometrium
    really the reason?
  attaches_to:
  - pathophysiology#Endometrial and Decidual Damage at the Lower Uterine Segment
  - pathophysiology#Low Implantation of the Blastocyst
  rationale: >-
    The endometrial-damage account is inferred entirely from the direction of the risk
    factors. No human study observes the implantation event, so the first two nodes of
    this pathograph rest on epidemiology plus the scar-specific mechanism borrowed from
    placenta accreta spectrum. The strongest single risk factor - assisted reproductive
    technology, RR 3.71 - is also the one least well explained by endometrial damage,
    since embryo transfer places the blastocyst mechanically; and the endometriosis data
    show an effect independent of conception method, which the damage account predicts
    but does not uniquely explain. The alternative account, that a large placenta
    spreads into the lower segment secondary to relative hypoxaemia, is the usual
    explanation offered for the smoking association and is not tested against the damage
    account by anything cited here.
differential_diagnoses:
- name: Placental Abruption
  description: >-
    The other major cause of second-half antepartum haemorrhage, and the one the
    painlessness of previa is meant to exclude. Curated separately.
  distinguishing_features:
  - Abruption bleeds with pain and uterine tenderness because blood accumulates behind an attached placenta; previa bleeds painlessly because the blood escapes freely through the cervix.
  - Ultrasound localises the placenta away from the internal os in abruption, and abruption is a clinical rather than a sonographic diagnosis.
  evidence:
  - reference: PMID:17012465
    reference_title: Placental abruption.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Placental abruption complicates about 1% of pregnancies and is a leading cause of vaginal bleeding in the latter half of pregnancy."
    explanation: >-
      Establishes abruption as the competing cause of second-half bleeding, at roughly
      twice the occurrence rate of previa, which is what makes it the differential that
      matters most at presentation.
  - reference: PMID:17012465
    reference_title: Placental abruption.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of abruption is a clinical one, and ultrasonography and the Kleihauer-Betke test are of limited value."
    explanation: >-
      The asymmetry that decides the differential: previa is diagnosed by transvaginal
      ultrasound, abruption clinically. A scan that localises the placenta away from the
      os therefore excludes previa without excluding abruption.
- name: Vasa Previa
  description: >-
    Fetal rather than maternal vessels crossing the os, most often arising when a
    second-trimester previa resolves and leaves velamentous vessels behind - so the two
    conditions share the trophotropic mechanism of this entry's migration node and are
    not merely look-alikes. Not currently a dismech entry.
  distinguishing_features:
  - The bleeding is fetal and small in volume but rapidly lethal to the fetus, whereas previa bleeding is maternal and threatens the mother.
  - Colour Doppler shows fetal vessels crossing over the cervix with no overlying placental tissue.
  evidence:
  - reference: PMID:37590981
    reference_title: Vasa Previa.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Vasa previa refers to fetal vessels (arterial or venous) unprotected by placental tissue or umbilical cord running through the membranes over or in close proximity to the internal cervical os."
    explanation: >-
      The definition that separates the two: the same anatomical location, but fetal
      vessels without placental tissue rather than placental tissue itself.
  - reference: PMID:37590981
    reference_title: Vasa Previa.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It has been proposed that the placenta grows preferentially toward the better-vascularized fundus of the uterus with advancing gestational age, and then the placental tissue overlying the less well-vascularized cervix and lower uterine segment undergoes atrophy, leaving behind exposed fetal vessels."
    explanation: >-
      Why this is a mechanistic relative and not just a look-alike: the proposed origin
      of vasa previa is this entry's own migration node running to completion over a
      velamentous cord.
- name: Placenta Accreta Spectrum
  description: >-
    Not an alternative diagnosis so much as a frequent superimposition - about one previa
    in nine. Curated separately.
  distinguishing_features:
  - Distinguished antenatally by lower-segment hypervascularity, placental lacunae with swirling flow, and loss of the clear zone.
  - Distinguished at delivery by failure of the placenta to separate; a previa without those markers separates normally.
  evidence:
  - reference: PMID:31722942
    reference_title: "Epidemiology of placenta previa accreta: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The incidence of PAS in women with a placenta previa was 11.10% (IQR 7.65-17.35)."
    explanation: >-
      Quantifies the overlap, which is why PAS is framed here as a superimposition to be
      actively excluded rather than an alternative diagnosis.
  - reference: PMID:34837427
    reference_title: "First-trimester ultrasound diagnostic features of placenta accreta spectrum in low-implantation pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lower uterine segment (uterovesical, subplacental and/or intraplacental) hypervascularity was present in 14/14 (100%) cases and only 1/12 (8.3%) controls (P < 0.001)."
    explanation: >-
      The discriminating marker, measured in a study whose controls are themselves
      persistent previas without PAS - which is exactly the comparison this differential
      requires.
notes: >-
  Scope. This entry covers placenta previa and the low-lying placenta. Placenta accreta
  spectrum has its own entry and is modelled here only where previa causes it: the
  Deficient Decidua Basalis Over the Uterine Scar node is the shared mechanism seen
  from the previa side, and the two entries should be read together rather than
  duplicated into each other.

  What the pathograph asserts and what it does not. The chain from a persistent previa
  onwards is well sourced - obstruction, haemorrhage, iatrogenic prematurity and the
  two independent routes to postpartum haemorrhage each carry their own citation. The
  first two nodes are weaker by construction and are flagged with a KNOWLEDGE_GAP
  discussion: no cited study observes a human implantation event, so the claim that
  endometrial damage causes low implantation is an inference from the uniform direction
  of the risk factors.

  On the bleeding mechanism. Every review states that lower-segment formation and
  cervical effacement shear the placental edge off the decidua, and it is almost
  certainly right, but none of the references assembled here demonstrates it. What is
  citable is the cervical-length literature, which is internally inconsistent - a
  CONTROVERSY discussion records the disagreement rather than picking the reading that
  suits the mechanism.

  Terminology. The historical complete/partial/marginal grading depended on cervical
  dilatation at examination and is not used. The subtypes here are the two
  transvaginal-ultrasound definitions in current use: covering the os, or within 20 mm
  of it.

  No datasets, deliberately. `just discover-datasets Placenta_Previa` returns six
  candidates and every one is a GENE_ONLY match whose actual subject is something else -
  four are placenta accreta spectrum transcriptomics (GSE211003, GSE211001, GSE210508,
  GSE104350 on abnormally invasive placenta), one is Hofbauer-cell chromatin
  (GSE255954), one is diabetic macrosomia (GSE162173). They resolve perfectly and none
  is about previa. This is the sibling-disease collapse the dataset-curation guidance
  warns about, arriving through the accreta overlap that the rest of this entry is at
  pains to keep separate, so the correct result is an empty `datasets:` block rather
  than a plausible one. Re-run the search if a previa-specific series appears.

  Prevalence denominators. Every prevalence record in this entry is per pregnancy, not
  per head of population, and the PAS record is conditional on previa. They are not
  comparable with the population prevalences elsewhere in the knowledge base, and each
  record says so in its own notes.

📚

References & Deep Research

References

2

PMID:39654466

Placenta Previa.

No top-level findings curated for this source.

PMID:32591150

Guideline No. 402: Diagnosis and Management of Placenta Previa.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Review round: add hemorrhage-management escalation ladder and two previa-specific trials · 2026-09-18T23:46:29Z · View source

Addresses the blocking review finding that treatments: jumped from blood transfusion straight to peripartum hysterectomy. Added five treatments between those two rungs: Uterotonic Therapy (oxytocin CHEBI:7872 + misoprostol CHEBI:63610), Tranexamic Acid (CHEBI:48669), Intrauterine Balloon Tamponade, Uterine Compression Sutures, and Pelvic Arterial Embolization (NCIT:C15917). Each carries target_mechanisms into 'Poorly Contractile Placental Bed in the Lower Uterine Segment', 'Maternal Sinus Haemorrhage from the Placental Bed', and/or the 'Post-partum Hemorrhage' phenotype, so those nodes no longer reach only a hysterectomy. treatment_effect distinguishes the two mechanistic classes: uterotonics and tranexamic acid INHIBIT, while tamponade and compression sutures BYPASS the poor lower-segment contractility rather than correcting it - which is the entry's own lower-segment thesis. Added clinical_trials: with NCT05133167 (balloon tamponade vs B-Lynch, n=60) and NCT05340205 (IV tranexamic acid vs intrauterine misoprostol, phase 4, n=81), both fetched with just fetch-reference. Both are cited for design only and graded evidence_source: OTHER, because neither registry record carries outcome values. Every CURIE was resolved against OLS at the time of writing rather than recalled. This caught three wrong identifiers suggested by the falcon deep-research report: oxytocin is CHEBI:7872 not CHEBI:30623, and misoprostol is CHEBI:63610 not CHEBI:7023. A fabricated HP:0500083 for postpartum hemorrhage was also caught by the pre-edit validation hook and replaced with HP:0011891, the term the entry's own phenotype already binds. therapeutic_modality is deliberately unset on two treatments, with the reason recorded in notes: on each - uterotonic therapy mixes a peptide with a small molecule in a single-valued slot, and catheter-delivered embolization fits neither SURGERY nor DEVICE as the enum uses them. Validation: just validate passes (schema, terms, references) with 75/75 snippets verified, up from 65. check-duplicate-keys, check-entity-refs, check-causal-targets, check-qualifier-terms and check-enum-values all clean.

Create: Placenta Previa (MONDO:0005918) · 2026-09-15T16:45:43Z · View source

Created kb/disorders/Placenta_Previa.yaml, anchored to MONDO:0005918 (placenta praevia). Selected off the obstetric coverage-gap list in issue #7837, where placenta previa has been on the "still absent" line since 2026-08-24. Verified absent before starting: no file, no use of the MONDO ID anywhere in kb/ or stubs/, no `claim` issue, and no open or closed PR mentioning previa. Deep research. `claude_code` was unreachable in this environment (not logged in) and `openai` 404'd on `o3-deep-research-2025-06-26`, so the committed report is `falcon` (Edison), 668 s, 51 citations. Its own validation reports 12/12 references verified, confabulation_rate 0.0, and one unresolved term (HP:0030916) which was not used. Its `needs_review: true` is driven by that term plus a MONDO label mismatch that is a template artifact - the report records the disease label as "if available". `just preflight-dr` returns SKIP because MONDO records no RO:0004003 causal gene for MONDO:0005918, the same non-Mendelian outcome the Bacterial Vaginosis and Pelvic Organ Prolapse runs on this list hit; gene-identity preflight does not apply and concordance was assessed manually instead. The report independently reproduced the pathograph built from the manual PubMed sweep - the previa/low-lying subtype split, low implantation on damaged endometrium, trophotropic resolution by differential growth rather than movement, the PAS branch via defective decidualisation over a scar, the same 11.10% PAS-in-previa figure and the same 5.4 mm/week migration rate - and independently stated that previa is a localisation disorder rather than an invasion disorder, which is the reason the entry keeps the invasion arm as a conditional branch. It contributed one substantive correction. It flagged that resolution estimates depend heavily on gestational age at detection and degree of overlap, citing a Research Square preprint (10.21203/rs.3.rs-1188255/v1, reported by falcon as "ArXiv", which is wrong). Rather than cite the preprint, I traced the same LoPPS cohort to its peer-reviewed sibling, PMID:35841836 (Placenta, 2022), and cited that: 62.5% of women whose previa persisted to 28 weeks still had previa at 36 weeks. That is recorded as a REFUTE item against the general reading of the ">98% resolve" figure, with a node-level note saying the two describe different starting points rather than reconciling them into one number. Evidence. 18 references, all newly fetched and committed. 65/65 snippets verified by `just validate`. Two deliberate disagreements are curated rather than smoothed: the cervical-length literature (PMID:19173235 SUPPORT for severe haemorrhage and REFUTE for bleeding as such, from the same 59-woman cohort, against PMID:31434519's larger cohort finding the association) carries a CONTROVERSY discussion; and the resolution figures above. Two NO_EVIDENCE items record sources that explicitly decline to judge: Cresswell on whether regional variation is ethnic, and Oyelese on uterus-preserving management of accreta. HP:0003811 Neonatal death was deliberately left unbound. It exists in HPO but sits under Mortality/Aging rather than under HP:0000118, so it is outside the PhenotypeTerm dynamic-enum root and binding it fails term validation. This is a fourth instance of the enum-root gap issue #7837 already records for HP:0003826 Stillbirth, HP:0009800 Maternal diabetes and HP:0100602 Preeclampsia; the phenotype keeps its `preferred_term` and a note, as Intrahepatic Cholestasis of Pregnancy does for stillbirth. No clinical_trials block, though one was attempted. PMID:35841836 registers ChiCTR2100054068, and `just ictrp-fetch ChiCTR2100054068` reports that ICTRP has no record for that identifier. Per the ICTRP guidance an unresolvable registry ID is not recorded, so the trial is omitted rather than curated from the paper's own transcription. No datasets block, and that is a triage result rather than an omission. `just discover-datasets Placenta_Previa` returns six candidates, all GENE_ONLY, and every one is about something else - four are placenta accreta spectrum transcriptomics, one is Hofbauer-cell chromatin, one is diabetic macrosomia. They all resolve; none is about previa. Recorded in the entry's notes as the sibling-disease collapse the dataset guidance warns about. Validation. `just validate` passes (schema, terms, references; 65/65 snippets). `just compliance` reports 81.7% global. All deterministic gates clean: check-duplicate-keys, check-entity-refs, check-causal-targets, check-qualifier-terms, check-enum-values, check-folded-hyphens, check-snippet-length, check-title-snippets, check-snippet-grading, check-environmental-evidence. check-environmental-evidence initially failed on the Assisted Reproductive Technology exposure, which carried evidence only on its influences_mechanisms link and not at entry level; entry-level evidence was added rather than a waiver. `just validate-disorders` run over the changed files as the final batched check. One truncated snippet was caught and fixed during authoring: a quote from PMID:17012465 initially ended on "is a clinical one, and". Completed to the full sentence - the same defect class flagged in the PR #9414 review.

Falcon ▸

Placenta Previa (MONDO:0005918): Disease-Characteristics Research Report

Edison Scientific Literature 51 citations 2026-09-15T16:21:28.772880

Placenta Previa (MONDO:0005918): Disease-Characteristics Research Report

Executive summary

Placenta previa is a pregnancy-specific anatomical disorder in which placental tissue overlies the internal cervical os. Contemporary nomenclature reserves placenta previa for tissue covering the os and uses low-lying placenta when the placental edge is near, but does not cover, the os. It is not the same disease as placenta accreta spectrum (PAS), although previa—especially over a previous cesarean scar—is a major PAS risk context. The best-supported pathophysiology is abnormal low implantation followed by mechanical separation and bleeding as the lower uterine segment develops and the cervix changes. It is a complex, multifactorial condition, not a validated monogenic disorder. (fan2017theincidenceof pages 1-2, jenabi2023theassociationbetween pages 1-2)

The overall prevalence is approximately 5.2 per 1,000 pregnancies. Among affected pregnancies, meta-analytic estimates are 51.6% for antepartum hemorrhage, 22.3% for postpartum hemorrhage, and 11.1% for concomitant PAS, although definitions and populations are heterogeneous. Prior cesarean delivery, other endometrial–myometrial injury, advanced maternal age, multiparity, smoking, assisted reproductive technology (ART), and previous previa are the principal epidemiologic risk factors. (jauniaux2019epidemiologyofplacenta pages 3-4, fan2017theincidenceof pages 1-2, jenabi2023theassociationbetween pages 1-2, fan2017prevalenceofantepartum pages 1-2, gurolurganci2011riskofplacenta pages 1-2)

Domain	Best quantitative finding	Evidence type/year	Source DOI or NCT
Prevalence	5.2 cases per 1,000 pregnancies (0.52%) (jenabi2023theassociationbetween pages 1-2)	Systematic-review estimate cited in 2023	10.1186/s12887-023-04433-z
Antepartum hemorrhage (APH)	51.6% (2,347/4,687; 95% CI 42.7–60.6%; 29 studies; I²=97.9%) (fan2017prevalenceofantepartum pages 1-2)	Systematic review/meta-analysis, 2017	10.1038/srep40320
Postpartum hemorrhage (PPH)	22.3% (95% CI 15.8–28.7%; 11 studies; 5,146 pregnancies); 27.4% for previa versus 14.5% for low-lying placenta (fan2017theincidenceof pages 1-2)	Systematic review/meta-analysis, 2017	10.1371/journal.pone.0170194
Placenta accreta spectrum (PAS)	Median PAS incidence among pregnancies with placenta previa: 11.10% (IQR 7.65–17.35%) (jauniaux2019epidemiologyofplacenta pages 3-4)	Systematic review/meta-analysis, 2019	10.1136/bmjopen-2019-031193
Prior cesarean delivery	Second-birth previa: 8.7/1,000 after prior cesarean versus 4.4/1,000 after vaginal birth; adjusted OR 1.60 (95% CI 1.44–1.76; n=399,674) (gurolurganci2011riskofplacenta pages 1-2)	Population cohort plus meta-analysis, 2011	10.1186/1471-2393-11-95
Fetal growth	IUGR/SGA: 8.7% with previa versus 5.8% in controls; pooled OR 1.19 (95% CI 1.10–1.27; 13 studies; 1,593,226 singleton pregnancies) (balayla2019placentapreviaand pages 1-2)	Systematic review/meta-analysis, 2019	10.1515/jpm-2019-0116
Congenital abnormalities	Crude OR 1.81 (95% CI 1.34–2.28); adjusted OR 6.38 (95% CI 1.47–11.30); substantial heterogeneity (eight studies) (jenabi2023theassociationbetween pages 1-2)	Systematic review/meta-analysis, 2023	10.1186/s12887-023-04433-z
First-trimester miRNA signature	Seven-miRNA panel: AUC 0.937, sensitivity 100.0%, specificity 83.75%; 24 future-previa and 80 control pregnancies (hromadnikova2024abnormalmicrornaexpression pages 1-2)	Retrospective original study, 2024	10.3389/fmed.2024.1469855
Pharmacologic PPH prevention trial	Completed phase 4 randomized trial; n=81; IV tranexamic acid versus intrauterine misoprostol versus oxytocin-only control (NCT05340205 chunk 1)	Clinical trial, completed 2023	NCT05340205
Surgical PPH prevention trial	Completed randomized trial; n=60; balloon tamponade versus B-Lynch compression suture (NCT05133167 chunk 1)	Clinical trial, completed 2021	NCT05133167

Table: Compact quantitative evidence covering prevalence, hemorrhage, PAS, major risk and outcome associations, a preliminary molecular biomarker, and completed interventional trials. Estimates should be interpreted in light of observational designs and substantial heterogeneity in several meta-analyses.

1. Disease information

Definition and classification

Placenta previa is complete or partial placental coverage of the internal cervical os. A 2023 systematic review states directly: “Placenta previa is the complete or partial coverage of the internal cervical os with the placenta.” Low-lying placenta is distinct: placental tissue is close to, but does not overlie, the os. Older terminology divided previa into marginal, partial, and complete forms; contemporary practice generally classifies cases by whether the placenta covers the os and by the measured placental-edge–os distance. (fan2017theincidenceof pages 1-2, jenabi2023theassociationbetween pages 1-2, hromadnikova2024abnormalmicrornaexpression pages 1-2)

This distinction matters clinically. In a 4,490-pregnancy cohort, complete previa had stronger associations with PAS, severe postpartum hemorrhage, hemorrhagic shock, and hysterectomy than low-lying placenta; marginal and partial categories were less reproducible by ultrasound and had broadly similar outcomes. (bi2021effectoftypes pages 4-5)

Identifiers and synonyms

MONDO: MONDO:0005918, placenta previa.
ICD-10-CM: O44.-, placenta previa; subcodes distinguish hemorrhage, trimester, and unspecified forms. The English population cohort identified cases with ICD-10 O44. (gurolurganci2011riskofplacenta pages 1-2)
MeSH: D010923, Placenta Previa. (NCT05133167 chunk 1)
Common synonyms: placenta praevia, placental previa, low implantation of placenta; historical terms include marginal, partial/incomplete, total/complete, minor, and major placenta previa.
ICD-11: categorized within maternal disorders predominantly related to pregnancy/placental location; implementation-specific code verification is recommended before database loading.
OMIM/Orphanet: no dedicated Mendelian-disease entry is expected because this is an acquired, multifactorial obstetric condition rather than a monogenic syndrome.

The evidence summarized here is aggregated disease-level evidence from systematic reviews, registries, cohorts, and trials. It is not an individual EHR record, although one major study used de-identified English Hospital Episode Statistics. (gurolurganci2011riskofplacenta pages 1-2)

2. Etiology, risk, and protective factors

Causal framework

The exact initiating cause is unknown. The dominant model is that implantation occurs abnormally low because the upper uterine endometrium is relatively unfavorable or because scarred lower-segment tissue alters implantation and decidualization. This model is biologically plausible and consistent with epidemiology, but low implantation is not reducible to one molecular lesion.

Established or strongly supported risk factors

Prior cesarean delivery: in 399,674 English second births, previa occurred in 8.7/1,000 after a first cesarean versus 4.4/1,000 after vaginal birth; adjusted OR 1.60 (95% CI 1.44–1.76). A 37-study meta-analysis gave pooled OR 2.20 (1.96–2.46). The authors concluded: “There is an increased risk of placenta previa in the subsequent pregnancy after CS delivery at first birth.” (gurolurganci2011riskofplacenta pages 1-2)
Other uterine/endometrial injury: curettage, induced or spontaneous abortion, myomectomy, manual placental removal, and other intrauterine operations are repeatedly associated. These associations support, but do not prove, the scar/decidualization mechanism. (sahu2024maternalandperinatal pages 2-3, jenabi2023theassociationbetween pages 1-2)
Previous placenta previa: recurrence has been reported at approximately 4–8%. (balayla2019placentapreviaand pages 1-2)
Advanced maternal age and multiparity: consistent epidemiologic associations; interaction between age, parity, cumulative uterine procedures, and conception method likely contributes.
ART and infertility: a 2021 Chinese IVF cohort found that, relative to spontaneous conception, adjusted odds of previa varied by infertility subgroup: tubal disease 2.70 (95% CI 1.59–4.59), endometriosis 9.33 (4.22–20.62), male-factor infertility 4.14 (2.23–7.68), and mixed infertility 4.73 (1.83–12.21). This suggests contributions from both treatment and underlying reproductive pathology. (wang2021pregnancyoutcomesof pages 1-2)
Smoking: consistently identified by reviews as a modifiable association, plausibly through placental hypoxia or compensatory enlargement, but direct mechanistic proof is limited. (sahu2024maternalandperinatal pages 1-2, jenabi2023theassociationbetween pages 1-2)
Multiple gestation and male fetus: reported associations, but less actionable and less consistently quantified. (sahu2024maternalandperinatal pages 2-3, hromadnikova2024abnormalmicrornaexpression pages 1-2)

Genetic, infectious, and environmental factors

No causal gene, susceptibility locus with accepted clinical validity, chromosomal abnormality, founder mutation, or Mendelian inheritance pattern has been established. Therefore, penetrance, carrier frequency, anticipation, germline mosaicism, and consanguinity are not applicable. Routine ClinVar/ClinGen-style variant annotation is inappropriate.

No bacterium, virus, fungus, or parasite is established as a cause. No specific occupational toxicant, radiation exposure, pollutant, diet, alcohol pattern, or medication has a validated causal relationship. Smoking is the main reproducible lifestyle association.

Protective factors and gene–environment interaction

No validated protective allele, diet, supplement, or prophylactic drug prevents previa. Avoiding medically unnecessary primary cesarean delivery and smoking cessation may reduce population risk, but neither guarantees prevention. No replicated gene–environment interaction has been demonstrated. The clinically relevant interaction is instead uterine scar × subsequent implantation and possibly infertility biology × ART procedure. (wang2021pregnancyoutcomesof pages 1-2, gurolurganci2011riskofplacenta pages 1-2)

3. Phenotypes

Placenta previa is often asymptomatic when first found sonographically. Its classic symptomatic phenotype is sudden, painless, bright-red vaginal bleeding in the second half of pregnancy, usually episodic or recurrent and ranging from spotting to life-threatening hemorrhage.

Antepartum vaginal hemorrhage: symptom/sign; adult pregnancy onset, episodic and severity-variable. Meta-analysis of 29 studies and 4,687 affected women estimated 51.6% (95% CI 42.7–60.6%; I² 97.9%). Suggested HPO: HP:0001892 Abnormal bleeding and HP:0030972 Vaginal hemorrhage; an obstetric-specific ontology term should be preferred where available. (fan2017prevalenceofantepartum pages 1-2)
Postpartum hemorrhage: clinical sign, acute peripartum onset, potentially severe. Eleven studies involving 5,146 women gave pooled incidence 22.3% (15.8–28.7%); the estimate was 27.4% for previa versus 14.5% for low-lying placenta. Suggested HPO: HP:0011891 Postpartum hemorrhage. (fan2017theincidenceof pages 1-2)
Maternal anemia/hypovolemia/hemorrhagic shock: laboratory and clinical consequences of blood loss; severity depends on bleeding. Suggested HPO: HP:0001903 Anemia, HP:0033392 Hypovolemia, and HP:0031273 Hemorrhagic shock where validated locally. (sahu2024maternalandperinatal pages 1-2, jenabi2023theassociationbetween pages 1-2)
Preterm labor/delivery: downstream obstetric manifestation from bleeding or indicated delivery. Approximately 5% of all preterm deliveries have been attributed to previa in the reviewed evidence. Suggested HPO: HP:0001622 Premature birth. (sahu2024maternalandperinatal pages 3-5)
Fetal growth restriction/SGA: generally mild association. Across 1,593,226 singleton pregnancies, growth abnormality occurred in 8.7% with previa versus 5.8% in controls; pooled OR 1.19 (1.10–1.27; I² 94%). The authors’ conclusion was: “Neonates from pregnancies with placenta previa have a mild increase in the risk of IUGR/SGA.” Suggested HPO: HP:0001511 Intrauterine growth retardation, HP:0001518 Small for gestational age. (balayla2019placentapreviaand pages 1-2)
Low birth weight, low Apgar score, respiratory distress, NICU admission, stillbirth/neonatal death: mainly mediated by prematurity and hemorrhage rather than a fetal-intrinsic disorder. Suggested HPO: HP:0001518, HP:0030916 Neonatal respiratory distress, HP:0003811 Neonatal death, and HP:0003826 Stillbirth, subject to terminology validation. (sahu2024maternalandperinatal pages 3-5, jenabi2023theassociationbetween pages 1-2)
Congenital abnormalities: a 2023 eight-study meta-analysis reported crude OR 1.81 (1.34–2.28) and adjusted OR 6.38 (1.47–11.30), but heterogeneity was extreme (I² 80.6–97.9%), so causality and the adjusted magnitude are uncertain. (jenabi2023theassociationbetween pages 1-2)

Quality-of-life studies using EQ-5D, SF-36, or PROMIS are sparse. Practical burden includes emergency admission, activity disruption, anxiety about recurrent hemorrhage, prolonged inpatient observation, transfusion, operative morbidity, preterm neonatal hospitalization, and possible fertility loss after hysterectomy.

4. Genetic and molecular information

Clinical genetics

There are no validated causal genes, pathogenic variants, modifier genes, chromosomal abnormalities, or clinically actionable pharmacogenomic markers for isolated placenta previa. WES, WGS, gene panels, single-gene testing, CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing are not indicated for diagnosing maternal previa. Fetal genetic testing follows ordinary prenatal indications—for example, fetal anomaly or abnormal aneuploidy screening—not the placental location alone.

Emerging molecular profiling

A 2024 retrospective study compared first-trimester whole-blood microRNAs in 24 singleton pregnancies later developing isolated previa and 80 controls. Fifteen miRNAs were downregulated, including miR-20b-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-103a-3p, miR-130b-3p, miR-133a-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-342-3p, and miR-574-3p. A seven-miRNA model achieved AUC 0.937, 100% sensitivity, and 83.75% specificity; 75% of future cases were detected at a 10% false-positive rate. The authors appropriately cautioned: “Consecutive large-scale analyses must be performed to verify the reliability” of the model. This is preliminary association/prediction evidence, not a diagnostic assay or proof of causal gene regulation. Published 3 December 2024; DOI: 10.3389/fmed.2024.1469855. (hromadnikova2024abnormalmicrornaexpression pages 1-2)

No reproducible placenta-previa-specific proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, CRISPR-screen, or epigenome signature is clinically validated.

5. Environmental and lifestyle information

Smoking is the principal modifiable exposure associated with previa. Prior uterine instrumentation and cesarean delivery are iatrogenic/anatomical exposures rather than environmental toxins. ART is a reproductive-technology exposure whose association varies by infertility diagnosis. Evidence is insufficient for a previa-specific role of air pollution, endocrine disruptors, occupational agents, radiation, exercise, diet, alcohol, or infection. (wang2021pregnancyoutcomesof pages 1-2, jenabi2023theassociationbetween pages 1-2, gurolurganci2011riskofplacenta pages 1-2)

Suggested chemical ontology terms for treatment—not etiology—include CHEBI:30623 oxytocin, CHEBI:48669 tranexamic acid, and CHEBI:7023 misoprostol, with identifier verification before ingestion.

6. Mechanism and pathophysiology

Ordered causal chain

Prior uterine scarring/endometrial injury, altered implantation biology, ART-related factors, or an unknown initiating determinant leads to implantation of the blastocyst in the lower uterine segment; this first mechanistic link is strongly supported epidemiologically but incompletely demonstrated molecularly. (wang2021pregnancyoutcomesof pages 1-2, gurolurganci2011riskofplacenta pages 1-2)
Low implantation leads to placental tissue reaching or covering the internal cervical os, producing the defining anatomical lesion. (fan2017theincidenceof pages 1-2, jenabi2023theassociationbetween pages 1-2)
Growth of the uterus and formation of the lower uterine segment lead to apparent placental “migration” or resolution in many early cases through differential uterine growth/trophotropism rather than physical movement of the placenta. Persistent complete/major previa is more likely after prior cesarean and with greater initial overlap. (sahu2024maternalandperinatal pages 6-7, wei2022dynamicchangeof pages 6-9)
If previa persists, lower-segment stretching, cervical effacement/dilatation, or uterine contractions leads to shear at the relatively inelastic placental attachment, resulting in partial placental separation and maternal-vessel disruption; this mechanical explanation is biologically plausible and widely accepted, though direct experimental demonstration is limited. (balayla2019placentapreviaand pages 1-2)
Vessel disruption leads to painless antepartum bleeding, which may recur and branch:
Maternal branch: ongoing blood loss leads to anemia, hypovolemia, shock, transfusion, emergency cesarean delivery, intensive care, and occasionally hysterectomy or death. (sahu2024maternalandperinatal pages 1-2, jenabi2023theassociationbetween pages 1-2, fan2017prevalenceofantepartum pages 1-2)
Fetal branch: hemorrhage and urgent delivery lead to fetal hypoxia and prematurity, which result in low birth weight, respiratory morbidity, NICU admission, and increased perinatal mortality. (sahu2024maternalandperinatal pages 3-5)
Implantation over a scar with defective decidualization may branch into PAS, in which villi abnormally adhere to or invade myometrium; PAS then markedly amplifies surgical hemorrhage and adjacent-organ injury. Previa itself and PAS must not be conflated. (sahu2024maternalandperinatal pages 5-6, jauniaux2019epidemiologyofplacenta pages 3-4)
Placental separation after delivery plus poor contractility of the lower uterine segment leads to postpartum hemorrhage, potentially requiring uterotonics, antifibrinolytic therapy, tamponade, compression sutures, arterial control, or hysterectomy. (NCT05340205 chunk 1, NCT05133167 chunk 1, fan2017theincidenceof pages 1-2)

Cellular, molecular, and tissue detail

The dominant cells are decidual stromal cells, extravillous trophoblasts, syncytiotrophoblasts, uterine smooth-muscle cells, and maternal endothelial cells. Unlike PAS, uncomplicated previa is principally a localization disorder; excessive trophoblast invasion is not required.

A small 2023 histopathology study compared 20 previa, 20 accreta, and 20 control placentas. Previa sections showed pyknotic nuclei in muscle cells, vascular dilatation and fibrinoid structures, and dense intervillous erythrocyte accumulation. These findings are hypothesis-generating because the sample was small and the journal/reporting quality limits generalizability. Published 15 October 2023; DOI: 10.22270/jddt.v13i10.6235. (erdogan2023histopatologicalchangesin pages 1-2)

Suggested GO biological-process terms include GO:0007566 embryo implantation, GO:0001892 embryonic placenta development, GO:0042060 wound healing, GO:0001525 angiogenesis, GO:0007599 hemostasis, GO:0007596 blood coagulation, GO:0008285 negative regulation of cell proliferation only where experimentally supported, and terms for smooth-muscle contraction and extracellular-matrix organization. Suggested Cell Ontology terms include CL:0000351 trophoblast, CL:0000525 syncytiotrophoblast cell, decidual stromal cell, vascular endothelial cell (CL:0000115), and smooth muscle cell (CL:0000192); exact releases should be verified.

Subcellular protein misfolding, aggregation, channelopathy, enzyme deficiency, autophagy failure, or a specific metabolic block has not been demonstrated. Similarly, Wnt, MAPK, PI3K–AKT, mTOR, or immune pathways should not be asserted as causal for isolated previa based only on general placental biology.

7. Anatomical structures affected

Primary organ: placenta and gravid uterus.
Primary site: lower uterine segment and internal cervical os; suggested terms: UBERON:0001987 placenta, UBERON:0000995 uterus, UBERON:0000002 uterine cervix, subject to release verification.
Tissue interface: decidua basalis/endometrium, chorionic villi, intervillous maternal blood space, myometrium, and lower-segment vasculature.
Secondary involvement: maternal cardiovascular/hematologic systems during hemorrhage; fetal/neonatal respiratory and neurologic risk through hypoxia and prematurity. Bladder, ureters, and pelvic structures are generally threatened only when PAS/percreta coexists.
Lateralization: not applicable. Clinically relevant location descriptors are anterior versus posterior, complete versus incomplete coverage, and relation to a cesarean scar.
Subcellular localization: no disease-defining organelle lesion is known.

8. Temporal development

The lesion originates during implantation and placentation but is usually detected during routine mid-trimester ultrasound. Screening at approximately 18–22 weeks is followed by repeat localization later in pregnancy when the placenta is low. (hromadnikova2024abnormalmicrornaexpression pages 1-2)

Many second-trimester low placentas resolve as the lower segment develops. One review reports apparent migration around 5.4 mm/week and resolution of more than 98% of suspected second-trimester low-lying/previa findings, but estimates depend heavily on initial overlap and case definition. By contrast, a selected cohort of major second-trimester previa found 71.2% persistent previa at delivery, illustrating why low-lying and major/complete disease cannot be pooled. (sahu2024maternalandperinatal pages 6-7, wei2022dynamicchangeof pages 6-9)

Clinical bleeding is acute and episodic, usually in the late second or third trimester; recurrence and severity are unpredictable. The critical windows are mid-trimester detection, third-trimester reassessment, onset of any bleeding, and planned delivery before labor. The condition ends with delivery and placental removal; it is not lifelong, although recurrence risk affects subsequent pregnancies.

9. Inheritance and population epidemiology

Overall prevalence is approximately 5.2/1,000 pregnancies (0.52%). A PAS-focused meta-analysis found median previa prevalence 0.56% (IQR 0.39–1.24), with marked heterogeneity. Regional and institutional estimates vary because of maternal age, parity, cesarean and ART rates, ultrasound practice, referral concentration, and diagnostic thresholds. (jauniaux2019epidemiologyofplacenta pages 3-4, jenabi2023theassociationbetween pages 1-2, hromadnikova2024abnormalmicrornaexpression pages 1-2)

This disease affects pregnant individuals with a placenta; fetal sex is not the defining sex distribution. The typical affected population is reproductive-age adults, with risk increasing at advanced maternal age. Some studies report higher rates among Asian and Black populations, but ethnicity may proxy differences in obstetric history, access, ascertainment, and social determinants; it should not be treated as a deterministic biological category. (sahu2024maternalandperinatal pages 2-3)

Inheritance is multifactorial/non-Mendelian. Penetrance, expressivity, anticipation, founder effects, carrier frequency, mosaicism, and variant geography are not applicable.

10. Diagnostics

Standard diagnostic pathway

Routine obstetric ultrasound identifies placental location.
If low placement is suspected, transvaginal ultrasound (TVUS) is the reference imaging method for accurately measuring the placental edge relative to the internal os; it is more accurate than transabdominal assessment and is considered safe when performed appropriately. (sahu2024maternalandperinatal pages 5-6)
Repeat TVUS in the third trimester determines persistence and informs delivery mode. After approximately 35 weeks, an edge–os distance under 2 cm is associated with a higher cesarean rate; complete coverage is a contraindication to vaginal delivery. (sahu2024maternalandperinatal pages 6-7)
In previa with prior cesarean or suspicious ultrasound, evaluate specifically for PAS. Findings include placental lacunae, loss of the retroplacental hypoechoic zone, myometrial thinning/interruption, and abnormal uterovesical or placental–myometrial vascularity. MRI is adjunctive for inconclusive ultrasound, posterior placenta, invasion mapping, or surgical planning—not routine previa diagnosis. (sahu2024maternalandperinatal pages 5-6)

Acute bleeding evaluation

Assess hemodynamic status, fetal heart rate, bleeding quantity, CBC/hemoglobin, blood type and antibody screen/crossmatch, coagulation studies when bleeding is substantial, and ultrasound. A sterile speculum examination may identify another source. Digital cervical examination should be avoided until previa has been excluded, because contact can precipitate severe hemorrhage. New bleeding generally warrants hospital assessment. (sahu2024maternalandperinatal pages 7-8)

Differential diagnosis

Placental abruption usually causes painful bleeding, uterine tenderness/hypertonus, or fetal compromise; vasa previa causes fetal bleeding after membrane rupture; other alternatives include labor-related bloody show, cervical ectropion/polyp, cervicitis, trauma, and genital-tract malignancy. PAS is a comorbidity/differential placental invasion disorder, not a synonym.

Biomarkers and screening

No blood, urine, tissue, or genetic biomarker is approved for diagnosis. The 2024 seven-miRNA model is exploratory and needs prospective external validation. Routine population ultrasound is effectively anatomical screening; there is no newborn, carrier, or cascade screening. (hromadnikova2024abnormalmicrornaexpression pages 1-2)

11. Outcome and prognosis

With prenatal recognition, blood availability, planned cesarean delivery, and multidisciplinary care, most patients survive and recover fully after delivery. Conventional five- or ten-year survival measures are not meaningful for this time-limited pregnancy complication.

Major maternal outcomes are recurrent antepartum hemorrhage, emergency delivery, postpartum hemorrhage, transfusion, anemia, shock, ICU admission, surgical injury, hysterectomy, and PAS. Median PAS incidence in a previa cohort was 11.10% (IQR 7.65–17.35). In a heterogeneous PAS-with-previa review, five maternal deaths occurred among 387 cases (1.3%); this figure pertains to the high-risk PAS subset, not uncomplicated previa. (jauniaux2019epidemiologyofplacenta pages 3-4, jauniaux2019epidemiologyofplacenta pages 4-5)

Perinatal prognosis is driven primarily by gestational age at delivery and hemorrhage. One reviewed estimate reported neonatal mortality of 10.7/1,000 in previa pregnancies versus 2.5/1,000 in other pregnancies (RR 4.3, 95% CI 4.0–4.8). Prematurity, low birth weight, fetal hypoxia, respiratory distress, and sepsis mediate much of this risk. (sahu2024maternalandperinatal pages 3-5)

Poor prognostic indicators include complete/major previa, anterior placenta over a cesarean scar, increasing numbers of prior cesareans, suspected PAS, recurrent or early bleeding, short cervix, emergency rather than planned delivery, anemia, and limited access to blood products or specialist surgery. Complete previa was the subtype most clearly associated with severe hemorrhage, shock, and hysterectomy in a large cohort. (bi2021effectoftypes pages 4-5)

12. Treatment and current implementation

There is no drug that relocates the placenta or cures previa. Management prevents and treats hemorrhage while optimizing fetal maturity.

Clinical algorithm

Asymptomatic, stable, preterm: expectant outpatient or inpatient management according to bleeding history, distance from hospital, support, laboratory status, and local guidance. Counsel about urgent presentation for bleeding, contractions, pain, or reduced fetal movement.
Bleeding: hospitalize or assess urgently; establish IV access, quantify blood loss, obtain CBC and type/crossmatch, monitor maternal hemodynamics and fetus, administer anti-D immunoglobulin to eligible RhD-negative patients, and resuscitate with balanced blood-component therapy when needed. (sahu2024maternalandperinatal pages 7-8)
Risk of preterm delivery: antenatal corticosteroids are used according to gestational-age guidance; magnesium sulfate is used for fetal neuroprotection when very preterm delivery is imminent, not to treat previa itself. Tocolysis may occasionally permit steroid completion in a stable patient but is inappropriate with major ongoing hemorrhage or maternal/fetal instability.
Planned delivery: uncomplicated persistent complete previa is generally delivered by cesarean at 36–37 weeks; earlier delivery is indicated for uncontrolled or recurrent major bleeding, labor, rupture of membranes, or maternal/fetal compromise. Suspected PAS follows an earlier specialist pathway, often 34–35+6 weeks, and should not be managed as simple previa. (sahu2024maternalandperinatal pages 2-3, sahu2024maternalandperinatal pages 6-7)
Operative preparation: senior obstetric and anesthesia teams, neonatal support, large-bore access, crossmatched blood, hemorrhage protocol, uterotonics, cell salvage where available, and PAS/urology/interventional-radiology expertise when indicated.

Hemorrhage interventions

Oxytocin and other uterotonics treat uterine atony; tranexamic acid inhibits fibrinolysis and is established for treatment of postpartum hemorrhage. Mechanical and surgical options include intrauterine balloon tamponade, uterine compression sutures, uterine or internal iliac artery ligation/embolization, stepwise devascularization, and hysterectomy. These interventions treat bleeding, not placental location. (NCT05340205 chunk 1, NCT05133167 chunk 1, fan2017theincidenceof pages 1-2)

Suggested NCIT mappings include Cesarean Section, Blood Transfusion, Tranexamic Acid, Oxytocin, Misoprostol, Balloon Tamponade, Uterine Artery Embolization, Compression Suture, and Hysterectomy; exact NCIT codes should be checked against the target release.

Recent/experimental trials

NCT05340205, completed phase 4 randomized open-label trial, Cairo University, actual n=81: IV tranexamic acid 1 g before incision versus intrauterine misoprostol 400 µg versus oxytocin-only control, all with postpartum oxytocin; primary endpoint was cesarean blood loss. The registry had no result values in the retrieved record, so efficacy cannot be inferred. ClinicalTrials.gov. (NCT05340205 chunk 1)
NCT05133167, completed randomized open-label trial, Pakistan, n=60: Foley-balloon tamponade versus B-Lynch suture for prevention of hemorrhage; primary endpoint was 24-hour blood loss. No numerical results were available in the retrieved record. ClinicalTrials.gov. (NCT05133167 chunk 1)

Gene therapy, cell therapy, RNA therapy, immunotherapy, genotype-guided therapy, and precision oncology-style targeted treatment are not applicable. Pharmacogenomic testing is not standard.

13. Prevention

Primary prevention

No intervention reliably prevents low implantation. Population-level strategies include avoiding medically unnecessary cesarean delivery and uterine instrumentation, smoking cessation, and evidence-based ART practice. The cesarean cohort estimated that 359 first-birth cesareans would produce one additional previa in the next pregnancy, illustrating a modest individual but meaningful population effect. (gurolurganci2011riskofplacenta pages 1-2)

Secondary prevention

Routine mid-trimester placental localization, repeat TVUS for low placement, and targeted PAS assessment in patients with previa plus prior cesarean are the main early-detection strategies. Optimize maternal hemoglobin and arrange delivery at an appropriately resourced center.

Tertiary prevention

Prevent death and organ injury through planned delivery before labor, readily available blood products, standardized hemorrhage protocols, experienced multidisciplinary teams, antenatal corticosteroids when preterm birth is expected, and timely escalation from uterotonics to tamponade, embolization/surgery, or hysterectomy. (sahu2024maternalandperinatal pages 5-6, sahu2024maternalandperinatal pages 7-8)

Vaccination, antimicrobial prophylaxis directed at disease causation, genetic counseling, preimplantation genetic testing, carrier screening, and prophylactic gene-based interventions are not applicable. Counseling should instead address recurrence, cesarean-associated future risk, PAS risk, and reproductive planning.

14. Other species and natural disease

No well-characterized, naturally occurring veterinary disorder directly homologous to human placenta previa was identified in the retrieved literature. Placental anatomy and implantation differ markedly across species; the human discoid, hemochorial placenta and uniquely remodeled lower uterine segment/internal os make direct extrapolation difficult. Sporadic low placentation may occur in nonhuman primates or domestic animals, but there is no established breed predisposition, orthologous causal gene, OMIA syndrome, or zoonotic/transmissible process. Consequently, NCBI Taxon and VBO annotations should not be asserted beyond Homo sapiens (NCBI Taxon:9606) without case-specific veterinary evidence.

15. Model organisms and experimental systems

There is no validated mouse, rat, sheep, zebrafish, invertebrate, knockout, or transgenic model that faithfully reproduces human placenta covering the internal cervical os and its late-pregnancy mechanical hemorrhage. Rodent uterine and placental geometry limits face validity. Models of cesarean scarring, decidualization failure, ART, trophoblast invasion, PAS, placental hypoxia, or hemorrhage can illuminate component processes but are not placenta-previa models.

The most relevant systems are therefore:

human longitudinal ultrasound cohorts;
registry/EHR studies of cesarean, ART, and obstetric outcomes;
delivered human placenta and lower-segment histopathology;
primary trophoblast/decidual cultures and organoids for implantation biology;
maternal blood liquid-biopsy studies, including the preliminary first-trimester miRNA work. (hromadnikova2024abnormalmicrornaexpression pages 1-2, erdogan2023histopatologicalchangesin pages 1-2, gurolurganci2011riskofplacenta pages 1-2)

Their principal limitation is that tissues obtained at delivery reflect downstream consequences and cannot directly reconstruct implantation-site selection months earlier.

Evidence appraisal and knowledge gaps

The strongest evidence concerns anatomy, ultrasound diagnosis, prior cesarean risk, hemorrhage burden, and clinical management. Most etiologic evidence is observational and susceptible to confounding by age, parity, infertility, uterine surgery, and referral patterns. Meta-analytic heterogeneity is substantial for hemorrhage, growth, and congenital-anomaly estimates. Molecular studies remain small and largely unvalidated; there are no clinically established causal genes or omics tests. Priority research areas are prospective first-trimester prediction, standardized definitions separating previa from low-lying placenta and PAS, external validation of molecular biomarkers, optimal hemorrhage-prevention strategies, patient-reported outcomes, and long-term infant outcomes.

References

(fan2017theincidenceof pages 1-2): Dazhi Fan, Qing Xia, Li Liu, Shuzhen Wu, Guo Tian, Wen Wang, Song Wu, Xiaoling Guo, and Zhengping Liu. The incidence of postpartum hemorrhage in pregnant women with placenta previa: a systematic review and meta-analysis. PLoS ONE, 12:e0170194, Jan 2017. URL: https://doi.org/10.1371/journal.pone.0170194, doi:10.1371/journal.pone.0170194. This article has 174 citations and is from a peer-reviewed journal.
(jenabi2023theassociationbetween pages 1-2): Ensiyeh Jenabi, Saeid Bashirian, and Sahar Khoshravesh. The association between of placenta previa and congenital abnormalities: a systematic review and network meta-analysis. BMC Pediatrics, Nov 2023. URL: https://doi.org/10.1186/s12887-023-04433-z, doi:10.1186/s12887-023-04433-z. This article has 5 citations and is from a peer-reviewed journal.
(jauniaux2019epidemiologyofplacenta pages 3-4): Eric Jauniaux, Lene Grønbeck, Catey Bunce, Jens Langhoff-Roos, and Sally L Collins. Epidemiology of placenta previa accreta: a systematic review and meta-analysis. BMJ Open, 9:e031193, Nov 2019. URL: https://doi.org/10.1136/bmjopen-2019-031193, doi:10.1136/bmjopen-2019-031193. This article has 252 citations and is from a peer-reviewed journal.
(fan2017prevalenceofantepartum pages 1-2): Dazhi Fan, Song Wu, Li Liu, Qing Xia, Wen Wang, Xiaoling Guo, and Zhengping Liu. Prevalence of antepartum hemorrhage in women with placenta previa: a systematic review and meta-analysis. Scientific Reports, Jan 2017. URL: https://doi.org/10.1038/srep40320, doi:10.1038/srep40320. This article has 143 citations and is from a peer-reviewed journal.
(gurolurganci2011riskofplacenta pages 1-2): Ipek Gurol-Urganci, David A Cromwell, Leroy C Edozien, Gordon CS Smith, Chidimma Onwere, Tahir A Mahmood, Allan Templeton, and Jan H van der Meulen. Risk of placenta previa in second birth after first birth cesarean section: a population-based study and meta-analysis. BMC Pregnancy and Childbirth, 11:95-95, Nov 2011. URL: https://doi.org/10.1186/1471-2393-11-95, doi:10.1186/1471-2393-11-95. This article has 247 citations and is from a peer-reviewed journal.
(balayla2019placentapreviaand pages 1-2): Jacques Balayla, Jade Desilets, and Guy Shrem. Placenta previa and the risk of intrauterine growth restriction (iugr): a systematic review and meta-analysis. Journal of Perinatal Medicine, 47:577-584, Aug 2019. URL: https://doi.org/10.1515/jpm-2019-0116, doi:10.1515/jpm-2019-0116. This article has 65 citations and is from a peer-reviewed journal.
(hromadnikova2024abnormalmicrornaexpression pages 1-2): Ilona Hromadnikova, Katerina Kotlabova, and Ladislav Krofta. Abnormal microrna expression profile at early stages of gestation in pregnancies destined to develop placenta previa. Frontiers in Medicine, Dec 2024. URL: https://doi.org/10.3389/fmed.2024.1469855, doi:10.3389/fmed.2024.1469855. This article has 3 citations.
(NCT05340205 chunk 1): Noran Amin. Blood Loss During Cesarean Delivery in Placenta Previa Patients. Cairo University. 2022. ClinicalTrials.gov Identifier: NCT05340205
(NCT05133167 chunk 1): M. Awais Qarni. Balloon Tamponade Vs B-Lynch In Placenta Previa. CMH Jhelum. 2021. ClinicalTrials.gov Identifier: NCT05133167
(bi2021effectoftypes pages 4-5): Shilei Bi, Lizi Zhang, Zhijian Wang, Jingsi Chen, Jingman Tang, Jingjin Gong, Sushan Xie, Lin Lin, Luwen Ren, Shanshan Zeng, Lijun Huang, Shaoshuai Wang, Lili Du, and Dunjin Chen. Effect of types of placenta previa on maternal and neonatal outcomes: a 10-year retrospective cohort study. Archives of Gynecology and Obstetrics, pages 1-8, Jan 2021. URL: https://doi.org/10.1007/s00404-020-05912-9, doi:10.1007/s00404-020-05912-9. This article has 49 citations and is from a peer-reviewed journal.
(sahu2024maternalandperinatal pages 2-3): Shreya A Sahu and Deepti Shrivastava. Maternal and perinatal outcomes in placenta previa: a comprehensive review of evidence. May 2024. URL: https://doi.org/10.7759/cureus.59737, doi:10.7759/cureus.59737. This article has 31 citations.
(wang2021pregnancyoutcomesof pages 1-2): Jingxue Wang, Qiwei Liu, Boer Deng, Fang Chen, Xiaowei Liu, and Jiumei Cheng. Pregnancy outcomes of chinese women undergoing ivf with embryonic cryopreservation as compared to natural conception. Jan 2021. URL: https://doi.org/10.1186/s12884-020-03486-7, doi:10.1186/s12884-020-03486-7. This article has 40 citations and is from a peer-reviewed journal.
(sahu2024maternalandperinatal pages 1-2): Shreya A Sahu and Deepti Shrivastava. Maternal and perinatal outcomes in placenta previa: a comprehensive review of evidence. May 2024. URL: https://doi.org/10.7759/cureus.59737, doi:10.7759/cureus.59737. This article has 31 citations.
(sahu2024maternalandperinatal pages 3-5): Shreya A Sahu and Deepti Shrivastava. Maternal and perinatal outcomes in placenta previa: a comprehensive review of evidence. May 2024. URL: https://doi.org/10.7759/cureus.59737, doi:10.7759/cureus.59737. This article has 31 citations.
(sahu2024maternalandperinatal pages 6-7): Shreya A Sahu and Deepti Shrivastava. Maternal and perinatal outcomes in placenta previa: a comprehensive review of evidence. May 2024. URL: https://doi.org/10.7759/cureus.59737, doi:10.7759/cureus.59737. This article has 31 citations.
(wei2022dynamicchangeof pages 6-9): Sumei Wei, Xin Li, Tianjiao Liu, Rui Ding, Lu Wei, Conghong Fan, Dongmei Tang, Wen Xiong, Yalan Li, and Xiao Yang. Dynamic change of placenta previa from second trimester to delivery: a retrospective longitudinal study cohort. ArXiv, Jan 2022. URL: https://doi.org/10.21203/rs.3.rs-1188255/v1, doi:10.21203/rs.3.rs-1188255/v1. This article has 0 citations.
(sahu2024maternalandperinatal pages 5-6): Shreya A Sahu and Deepti Shrivastava. Maternal and perinatal outcomes in placenta previa: a comprehensive review of evidence. May 2024. URL: https://doi.org/10.7759/cureus.59737, doi:10.7759/cureus.59737. This article has 31 citations.
(erdogan2023histopatologicalchangesin pages 1-2): Gamze ERDOĞAN, Engin DEVECİ, Nurullah PEKER, İbrahim İBİLOĞLU, Yavuz TEKELİOĞLU, Dilek YAVUZ, Gül Ebru AKDENİZ, and Hasan ERDOĞAN. Histopatological changes in plasenta previa, plasenta acreata and normotensive plasentas in the 3rd trimestry of pregnancy. Journal of Drug Delivery and Therapeutics, 13(10):28-32, Oct 2023. URL: https://doi.org/10.22270/jddt.v13i10.6235, doi:10.22270/jddt.v13i10.6235. This article has 0 citations.
(sahu2024maternalandperinatal pages 7-8): Shreya A Sahu and Deepti Shrivastava. Maternal and perinatal outcomes in placenta previa: a comprehensive review of evidence. May 2024. URL: https://doi.org/10.7759/cureus.59737, doi:10.7759/cureus.59737. This article has 31 citations.
(jauniaux2019epidemiologyofplacenta pages 4-5): Eric Jauniaux, Lene Grønbeck, Catey Bunce, Jens Langhoff-Roos, and Sally L Collins. Epidemiology of placenta previa accreta: a systematic review and meta-analysis. BMJ Open, 9:e031193, Nov 2019. URL: https://doi.org/10.1136/bmjopen-2019-031193, doi:10.1136/bmjopen-2019-031193. This article has 252 citations and is from a peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	12
Resolved	12
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	12
On topic	4
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	31
Resolved	29
Unresolved (possible confabulation)	1
Obsolete	0
Unverifiable	1
Terms whose name was checked	1
Terms named correctly	0
Terms named as a different term	1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0005918 (3 mentions) - the report calls it "if available"; MONDO calls it placenta praevia

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

HP:0030916 (1 mention) - HP does not contain this term

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: Taxon.

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Environmental Factors

Diagnosis

Prevalence

Clinical Burden

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Placenta Previa (MONDO:0005918): Disease-Characteristics Research Report

Executive summary

1. Disease information

Definition and classification

Identifiers and synonyms

2. Etiology, risk, and protective factors

Causal framework

Established or strongly supported risk factors

Genetic, infectious, and environmental factors

Protective factors and gene–environment interaction

3. Phenotypes

4. Genetic and molecular information

Clinical genetics

Emerging molecular profiling

5. Environmental and lifestyle information

6. Mechanism and pathophysiology

Ordered causal chain

Cellular, molecular, and tissue detail

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population epidemiology

10. Diagnostics

Standard diagnostic pathway

Acute bleeding evaluation

Differential diagnosis

Biomarkers and screening

11. Outcome and prognosis

12. Treatment and current implementation

Clinical algorithm

Hemorrhage interventions

Recent/experimental trials

13. Prevention

Primary prevention

Secondary prevention

Tertiary prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Evidence appraisal and knowledge gaps

Artifacts

Reference Validation

Term Validation

Terms the report names something else

Unresolved terms

Prefixes with no resolver